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Proton-coupled oligopeptide transporters (POTs) (i.e., PEPT1, PEPT2, PHT1 and 
PHT2) translocate various small peptide/mimetic across the biological membrane.  The 
first part of this dissertation focuses on investigating the transport properties of carnosine 
in kidney using SKPT cell cultures as a model of proximal tubular transport. Results 
demonstrated that carnosine is expected to have a substantial cellular accumulation in 
kidney due to its high influx clearance across apical membranes by PEPT2, but minimal 
tubular reabsorption into blood because of very low efflux clearance across basolateral 
membranes.   
Although the role of PEPT1 in intestinal absorption of small peptide/mimetics has 
been demonstrated previously by in vitro models, its relative importance during in vivo 
intestinal absorption is unknown.  Therefore, the objective of the second part of this 
dissertation is to delineate the relative importance of PEPT1 in intestinal absorption and 
disposition of small peptides/mimetics using wild-type and PEPT1 deficient mice, and 
glycylsarcosine (GlySar) as a model dipeptide substrate.  In situ intestinal perfusions and 
in vivo absorption models in mice were used in our investigations.  The results from our 
in situ studies show that PEPT1 is responsible for at least 90% of GlySar uptake in the 
small intestine and the transport protein exhibits low-affinity kinetics.  However, during 
in vivo conditions, the extent of reduction in absorption, due to the absence of PEPT1, 
 xv 
was lower than that of the in situ model.  Specifically, the extent of GlySar absorption 
was reduced by about 50% due to the absence of PEPT1 transporter during in vivo 
condition. When partial AUC0-120 min was used as an indicator of the rate of absorption, 
there was a 60% reduction in the rate of GlySar absorption in PEPT1 deficient mice 
compared to the wild-type animals.  With the exception of small intestine, PEPT1 had 
little effect on the tissue distribution of GlySar.  In conclusion, the present studies 
demonstrate, using both in situ and in vivo models, that PEPT1 ablation significantly 
reduces both the rate and extent of oral absorption of small peptide/mimetic substrates 
(i.e., GlySar).  These studies suggest that variability in intestinal PEPT1 (expression 
and/or activity) should exert a similar fate on peptide-like drugs.  
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Chapter 1  
 
RESEARCH OBJECTIVES 
Proton-coupled oligopeptide transporters (POTs) translocate various small 
peptides and peptidomimetics across the biological membrane via an inwardly directed 
proton gradient and negative membrane potential.  Up to this date, four members to this 
POT family, PEPT1, PEPT2, PHT1, and PHT2, have been identified in mammals.  POTs 
have significant physiological roles in the absorption and reabsorption of peptide-bound 
amino nitrogen as well as pharmacological roles in peptidomimetic drug absorption and 
disposition.  Due to their broad substrate specificity, varying capacity, and differential 
tissue distribution, POTs offer a promising target to drug design in effort to increase 
drugs’ oral bioavailability and/or tissue selection.  Current molecular cloning and 
characterization of POT members have increased our understanding of each peptide 
transporters’ structure, functional property, localization and physiological / 
pharmacological relevance.  
Carnosine (β-alanyl-L-histidine) is a naturally-occurring dipeptide that is highly 
concentrated in skeletal muscle and brain.  Besides being an endogenous substrate, 
carnosine is also taken exogenously as a dietary supplement for its antioxidant and free 
radical scavenging properties. Pharmacologically, carnosine has some renoprotective 
effects including acting as a protective factor in diabetic nephropathy and preventing 
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ischemia-induced renal injury. Carnosine is known to be transported by all four members 
of the POTs.  Despite carnosine’s significant pharmacological importance in the kidney, 
the renal disposition of this dipeptide has not been elucidated.  Previous studies in our lab 
have demonstrated that expression of PEPT2 in the kidney plays an important role in 
reabsorption of peptide/mimetics.  Therefore, the first research project in this dissertation 
focused on investigating the transport properties of carnosine in kidney using SKPT cell 
cultures as a model of proximal tubular transport, and to isolate the functional activities 
of renal apical and basolateral peptide transporters in this process.   
Following the ingestion of dietary protein (70- 100 g per day), proteins are 
converted into large peptides by gastric and pancreatic proteases in gastrointestinal lumen 
followed by a further hydrolysis into small peptides (80%) and free amino acids (20%) by 
various peptidases in the brush border membrane of intestinal epithelium. The final end 
products of protein digestion are absorbed into the enterocytes predominately in the form 
of di- and tri-peptides as supposed to free amino acids, suggesting an important role of 
peptide transporters in absorption of end product of protein meal in intestine.  Once 
inside the enterocytes, the majority of the di- and tripeptides undergo further hydrolysis 
into their constituent amino acids by cytoplasmic peptidases and exit the epithelial cells 
via different basolateral amino acid transporters.  A small amount of small peptides that 
are resistant to cytoplasmic peptidases exit the enterocytes intact across the basolateral 
membrane through a basolateral peptide transporter that has yet to be cloned.  Along the 
intestine, PEPT1 is strongly expressed on the apical membrane of small intestinal 
enterocyte (i.e., duodenum, jejunum, and ileum) with little or no expression in normal 
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colon. In addition, human and rat small intestine have been shown to express PHT1 and 
PHT2 transcripts, where PHT1 is expressed in the villous epithelium of small intestine.   
Among three POTs expressed along the intestine (i.e., PEPT1, PHT1, and PHT2), 
PEPT1 is believed to be the primary POT responsible for small intestinal absorption of 
small peptides/mimetic and peptide-like therapeutic agents.  As a consequence, PEPT1 is 
the most extensively studied transporter among the POT members.  However, most of the 
previous investigations were relied on non-physiological in vitro models that lack an 
intact blood supply.  Moreover, these studies did not reveal much information in respect 
to the relative importance of PEPT1 in relation to other peptide transporters (or other 
processes) in intestinal absorption.  In addition, PEPT1 is also expressed in other tissues 
such as kidney, lung, and liver where multiple POT members are expressed with 
overlapping substrate specificities, thus confounding an accurate assessment of PEPT1 in 
these tissues.   
Utilization of genetically-modified PEPT1 deficient mice offers a powerful tool to 
assess the relative importance of PEPT1 under the physiological condition for small 
peptides/mimetics absorption in the small intestine as well as disposition in other tissues.  
With this in mind, the goal second part of this dissertation project was to delineate the 
relative importance of PEPT1 in the intestinal absorption and disposition of 
peptide/mimetics via the utilization of wild-type and PEPT1 deficient mice.   
The specific aims of second research project were: 
 To define the relative importance of PEPT1 in the intestinal absorption of 
small peptides by defining the in situ intestinal transport properties of 
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glycylsarcosine (GlySar) in the intestine of PEPT1
+/+
 (wild-type) and PEPT1
-/-
 
(knockout) mice.   
 To delineate the relative importance of PEPT1 in vivo absorption and 
disposition of small peptide/mimetic by using glycylsarcosine (GlySar) as a 
model compound in PEPT1
+/+
 (wild-type) and PEPT1
-/-
 (knockout) mice. 
The results of current dissertation would provide valuable information on 
understanding the relative significance of PEPT1 in in vivo absorption and disposition of 
small peptide/mimetics (relative to other POTs and/or other processes).  Since PEPT1 is 
highly regulated by various factors (e.g., diets, hormones, growth factors, diurnal rhythm, 
drugs, and disease states), such understanding would have important implication in 
predicting intra and inter-individual variability of oral bioavailability of small peptides 
and peptide-like therapeutic agents. 
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Chapter 2  
 
BACKGROUND AND LITERATURE REVIEW: 
PROTON-COUPLED OLIGOPEPTIDE TRANSPORTERS 
Description and Relative Importance 
Proton-coupled oligopeptide transporters (POT) are membrane proteins that are 
responsible for translocating small peptides and peptidomimetics across the biological 
membrane.  Thus far, four members in POT super family have been identified, which 
include PEPT1 (SLC15A1), PEPT2 (SLC15A2), PHT1 (SLC A4), and PHT2 (SLC A3).  
Unlike many other known mammalian membrane transporters, they are neither ATP nor 
Na
+
 concentration gradient driven.  Rather, they are cotransported with proton energized 
by inwardly-directed proton concentration gradient and negative membrane potential 
across the biological membrane.  POT transporters transport wide spectrum of di- and tri-
peptides as well as a number of peptidomimetics with different conformation, size, 
polarity, and charges.  
PEPT1 was the first peptide transporter that was identified.  It was isolated and 
cloned from rabbit small intestine cDNA library (Fei et al., 1994).  Isolation of the rabbit 
PEPT1 cDNA has lead to the isolation and cloning of PEPT1 from human (Liang et al., 
1995), rat (Saito et al., 1995; Miyamoto et al., 1996), and mouse (Fei et al., 2000) 
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intestinal cDNA library.  It has been found that PEPT1 is highly homologous across 
species.  The genomic organization of human PEPT1 shows high similarity with its 
mouse orthologue (Urtti et al., 2001).  PEPT1 protein core mass is predicted to be 
approximately ~75 kDa (Saito et al., 1995).  PEPT2 was the next peptide transporter 
identified, and it was first cloned from human kidney cDNA library (Liu et al., 1995).  
PEPT2 was later also cloned from rabbit (Boll et al., 1996), rat (Saito et al., 1996), and 
mouse (Rubio-Aliaga et al., 2000) kidney cDNA library.  Molecular mass of PEPT2 
protein is approximately ~107 kDa (Boll et al., 1996).  PEPT2 transporter is a high 
affinity and low capacity transporter, whereas PEPT1 is a low affinity and high capacity 
transporter.  Recently, two additional peptide transporters, PHT1 (Yamashita et al., 1997) 
and PHT2 (Sakata et al., 2001), were cloned from rat brain cDNA library.  Unlike PEPT1 
and PEPT2, both PHT1 and PHT2 have shown to transport single amino acid L-histidine 
in addition to di- and tri-peptides in the same proton gradient manner.  There is still lack 
of information on functional roles of PHT1 and PHT2 in various tissues as well as their 
substrate specificities and transport mechanisms.  Human peptide transporter (HPT-1), a 
member of cadherin family, has been found in small intestine and shown to transport 
aminocephalosporins in H
+
 gradient dependent manner (Dantzig et al., 1994).  
The mammalian peptide transporters have both nutritional (physiological) and 
pharmacological importance.  It was a common belief that protein must be broken down 
into its free amino acid constituents in the gut lumen before the absorption could take 
place, and amino acid transporters are responsible for absorption of amino nitrogen in 
blood circulation.  However, later it has been establish that more than 50% of plasma 
amino acid pool is in peptide bound form (Seal and Parker, 1991), suggesting that di- and 
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tripeptides are absorbed intact in the small intestine;  Mathews has demonstrated that 
digestion of dietary protein in the intestinal lumen results in a mixture of small peptides 
and free amino acids, and they are absorbed by enterocytes  by two separate mechanisms, 
through intestinal peptide transporter and amino acid transporter, respectively (Matthews, 
1975).  Therefore, the primary physiological function of POTs in small intestine is to 
absorb small peptides arising from digestion of dietary protein.  Similarly in kidney, 
PEPT1 and PEPT2 sequentially reabsorb amino acids in peptide-bound form to conserve 
amino acid nitrogen which would be lost in urine otherwise.  
The pharmacological importance of peptide transporters are attributed to their 
roles in intestinal absorption and systemic exposure of peptidomimetics.  The intestinal 
peptide transporter absorbs orally active β-lactam antibiotics, ACE inhibitor, renin 
inhibitors, anticancer drug bestatin, and antiviral prodrug valacyclovir, and act as vehicle 
for their effective intestinal absorption.  Systemic exposure and therapeutic efficiency of 
these drugs are determined not only by their efficient intestinal absorption, but also by 
their half life in blood circulation.  Peptide transporters in kidney reabsorb theses 
peptidomimetics from glomerular filtrate, thus, increasing their half lives in circulation.  
The peptide transporters can also affect drug distribution and disposition in other organs.  
They are also good targets to design a prodrug to improve its systemic bioavailability and 
to alter its pharmacokinetic profile.   
Molecular Structure of POTs 
Mammalian POT transporters share many structural similarities.  Based on 
hydropathy analysis, POT transporters contain 12 putative transmembrane domains 
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(TMD) with both N- and C-terminals facing the cytosolic side.  They commonly posses 
an unusually large hydrophilic loop between TMD9 and TMD10.  POT proteins vary in 
size from 572-729 amino acids (Table 2.1).   PEPT1 proteins vary from 707 to 710 in 
amino acids depending on the species, whereas PEPT2 is consist of 729 amino acids 
regardless of the species.  POT proteins have number of potential N-glycosylation (2-7) 
sites and protein kinase recognition sites (0-3 PKA sites and 1-11 PKC sites) suggesting 
that POT transporters might be regulated by reversible phosphorylation.  The overall 
molecular structures of POT proteins are summarized in Table 2.1 (Fei et al., 1994; Liang 
et al., 1995; Liu et al., 1995; Saito et al., 1995; Boll et al., 1996; Miyamoto et al., 1996; 
Saito et al., 1996; Yamashita et al., 1997; Fei et al., 2000; Rubio-Aliaga et al., 2000; 
Sakata et al., 2001; Bhardwaj et al., 2006).  
PEPT1 and PEPT2 share high homology in amino acids sequence between 
species (80-90% amino acid identity between human, rat, mouse, and rabbit).  However, 
homology between different peptide transporters in a given species is relatively low.  
Human PEPT1 and PEPT2 share about 50% amino acid identity, where as that of rat 
PHT1 and rat PHT2 is about 50% too.   However, peptide/histidine transporters show 
even less amino acid homology to PEPT transporters, less than 20%.  Most of the 
conserved sequences occur within the putative transmembrane domains, whereas the 
sequence differences among the species and different transporters occur mostly in loops 
connecting the putative transmembrane domain, especially in large extracellular loop 
between TMD9 and TMD10.   
HPT-1, isolated from Caco-2 cell line, has been demonstrated to transport 
aminocephalosporins in H
+
 gradient dependent manner.  HPT-1 contains a single putative 
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transmembrane domain (Dantzig et al., 1994).  It shows very minimum homology to any 
known prokaryotic or eukaryotic peptide transporters, about 16% identity and 41% 
similarity to hPEPT1.  However, it has high homology with the cadherin family of cell 
adhesion protein (Dantzig et al., 1994).  On the other hand, some data suggest that HPT-1 
is not an actual H
+
 coupled oligopeptide transporter but rather a modulator of endogenous 
oligopeptide transporter in Caco-2 cells (Hediger et al., 1995).   
Tissue and Cellular Distribution of POTs   
PEPT1 is believed to be the primary peptide transporter in the small intestine that 
is responsible for absorption of small peptides from the digestion of dietary proteins.  
PEPT1 mRNA has been detected in the small intestine of a number of mammalian 
species such as rabbit (Fei et al., 1994), human (Liang et al., 1995), rat (Miyamoto et al., 
1996; Shen et al., 1999; Lu and Klaassen, 2006), and mouse (Lu and Klaassen, 2006).  
PEPT1 protein was also detected in small intestine (Saito et al., 1995; Ogihara et al., 
1996; Shen et al., 1999).  More specifically, PEPT1 in small intestine is confined to 
duodenum, jejunum and lesser extent to ileum segments.  In small intestine, PEPT1 is 
localized at the brush border membrane of the differentiated absorptive epithelial cells in 
villi tips, and not in mucus-secreting goblets cells or less differentiated epithelial cells in 
the crypts (Ogihara et al., 1996; Walker et al., 1998; Groneberg et al., 2001a).  Lower 
level of expression of PEPT1 mRNA was localized at brush border membrane of kidney 
proximal tubule cells of rabbit (Fei et al., 1994), human (Liang et al., 1995), rat 
(Miyamoto et al., 1996; Shen et al., 1999; Lu and Klaassen, 2006), and mouse (Lu and 
Klaassen, 2006).  Mouse renal PEPT1 mRNA was very low compared to that of rats.  In 
contrast, PEPT1 mRNA was detectable in mouse large intestine, but not in rat (Lu and 
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Klaassen, 2006).  Renal PEPT1 protein was detected by western blot in rat (Saito et al., 
1995; Shen et al., 1999) and mouse (Shen et al., 2003).  In kidney, PEPT1 is confined to 
brush border of S1 segment of renal proximal tubule (kidney cortex) (Shen et al., 1999).  
Lower level of PEPT1 mRNA has also been detected in other tissues such as liver, 
pancreas, lung, bile duct, ovary, placenta, testis, prostate, and even some expression in 
large intestine and stomach tissue (Fei et al., 1994; Liang et al., 1995; Herrera-Ruiz et al., 
2001; Knutter et al., 2002; Lu and Klaassen, 2006).  Via utilization of 
immunoflourescence microscopy and transport studies, PEPT1 was demonstrated to be 
expressed in membrane of lysosomal compartment of liver cells (Thamotharan et al., 
1997), renal cells (Zhou et al., 2000) and pancreatic cells (Bockman et al., 1997), rather 
than being  exclusively confined to plasma membrane.  
PEPT2 is primarily localized in the kidney and brain.  More specifically, PEPT2 
is found in brush border membrane of S2 and S3 segments of renal proximal tubule, the 
outer stripe of outer medulla (Smith et al., 1998; Shen et al., 1999).  PEPT2 mRNA (Liu 
et al., 1995; Shen et al., 1999) and protein (Shen et al., 1999; Rubio-Aliaga et al., 2000) 
expression have been detected in the kidney.  In brain, PEPT2 mRNA  was found to be 
localized in astrocytes, subependymal cells, ependymal cells, and the epithelial cells of 
choroid plexus (Berger and Hediger, 1999).  Recently PEPT2 protein expression in 
choroid plexus was confirmed by western blot (Shu et al., 2002).  Moreover, PEPT2 is 
also expressed in lung, muscle, liver, heart, mammary gland, eyes, pituitary gland, spleen, 
blood vessels, testis, prostate, ovary, and uterus (Boll et al., 1996; Doring et al., 1998a; 
Lu and Klaassen, 2006).  In lung, the expression of PEPT2 mRNA and protein were 
localized to alveolar type II pneumocytes, bronchial epithelium, and endothelium of 
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small arteries (Groneberg et al., 2001b).  In mammary gland, the PEPT2 is expressed in 
mammary gland epithelia (Groneberg et al., 2002).  In eyes, PEPT2 mRNA is localized in 
retina (Berger and Hediger, 1999).  
Expression of PHT1 mRNA was found in brain, eyes, lung, spleen, liver, heart, 
kidney, skeletal muscle, thymus, and throughout the GI tract (Yamashita et al., 1997; 
Botka et al., 2000; Herrera-Ruiz et al., 2001).  Specifically, PHT1 was localized in retina 
of eyes (Ocheltree et al., 2003).  In GI tract, hPHT1 protein was detected in stomach, 
duodenum, jejunum, ileum, and colon by western blot.  Immunohistochemical analysis 
have illustrated that PHT1 is localized at the villous epithelium in the small intestine 
(Bhardwaj et al., 2006).  
PHT2 mRNA is mostly found in lymphatic system, lung, spleen, thymus, and 
faintly in brain, liver, adrenal gland, heart, and the GI tract (Herrera-Ruiz et al., 2001; 
Sakata et al., 2001).  Unlike other POT members, PHT2 is found in lysosome rather than 
plasma membrane which was demonstrated by light and electron-microscopic analysis 
(Sakata et al., 2001).  Compared to PEPT1 and PEPT2, relatively little information is 
available for PHT1 and PHT2 in respect to their physiological roles, substrate 
specificities, and mechanisms of transport.   
Expression of HPT1 is observed in human colon, skeletal muscle, and faintly in 
the small intestine by RT-PCR and southern-blot analysis (Herrera-Ruiz et al., 2001).  A 
summary of tissue and cellular distributions of POTs is presented in Table 2.2.  
Protein Structure Activity Relationship  
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In order to use POT members as a drug delivery target, it is essential to 
understand the protein structure and substrate recognition mechanisms of these 
transporters.  Since direct structural approaches, such as crystallization, characterization 
by NMR or other spectroscopic methods, are limited to transmembrane protein, other 
methods including site-directed mutagenesis, construction of various chimeras, and 
computer modeling have been employed to elucidate the protein structure of peptide 
transporters. 
A number of single point mutations have been employed in PEPT1 and PEPT2, 
which have lead to the identification of several essential residues.  Since several of H
+
 
cotransporters are known to contain conserved specific histidyl residues, which are 
essential for catalytic activity of the transporters, Fei et al have investigated the histidyl 
residues in hPEPT1 and hPEPT2 using site-directed mutagenesis (Fei et al., 1997).  A 
partial alignment of amino acid sequences of rat, rabbit and human PEPT1 and PEPT2, 
revealed that His-57, His-121, and His-260 in PEPT1, His-87, His-142, and His-278 in 
PEPT2 are conserved in all three species.  They have found that His-57 in hPEPT1 and 
His-87 in hPEPT2 are absolutely essential amino acids in transport function of these 
transporters.  Both of these histidyl residues are located near the extracellular surface of 
the second putative transmembrane domain (Fei et al., 1997).  His-57 as the key residue 
serving as the predominant proton binding sites in hPEPT1 was further confirmed by 
Uchiyama et al (Uchiyama et al., 2003).  Using the same method, Terada and coworkers 
have shown that His-57 (TMD2) and His-121 (TMD4) in rat PEPT1 are involved in 
substrate recognition (Terada et al., 1996).  Additional studies have also suggested that 
His-57 and His-121 are intimately involved in the binding of H
+
 ion and substrate 
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recognition in rabbit PEPT1 (Chen et al., 2000).  It was also demonstrate that His-57 and 
its surrounding aromatic residues, such as Tyr-56 and Tyr-64, are essential for normal 
function of PEPT1 (Chen et al., 2000).  This finding is consistent with the concept that 
aromatic residues stabilize the charges within membrane electric field (Chen et al., 2000).   
Meredith and coworkers also have reported that Arginine-282 in TMD7 plays a key role 
in the rabbit PEPT1 proton coupling pathway (Meredith, 2004)  and it forms a charge pair 
with D-341 in TMD8 (Kulkarni et al., 2007; Pieri et al., 2008).  Mutation at Trp-294 and 
Gly-595 significantly reduce substrate uptake, suggesting the involvement of these 
residues in transport process (Bolger et al., 1998).  A combination of transport assays, 
luminometry and site-directed mutagenesis have suggested that PEPT1 is a multimer, 
probably a tetramer (Panitsas et al., 2006).  
Construction of various chimeras consisting of variable segments of PEPT1 and 
PEPT2 has helped to identify protein domains that are relevant to substrate binding and 
transport processes.  With this approach, it has been revealed that phenotypical 
characteristic of PEPT2, such as substrate affinity, substrate specificity, 
electrophysiological parameters, and pH-dependency, are determined by its first half of 
the transport protein up to TMD9 or its amino terminal region, not by the large 
extracellular loop between TMD9 and TMD10 (Doring et al., 1996; Doring et al., 2002).  
Similar finding was also demonstrate by Terada and coworkers that N-terminal half of 
the rat PEPT1 and PEPT2 contain both H
+
 binding site and substrate recognition site 
(Terada et al., 2000a).  Construction of chimeric PEPT1-PEPT2 protein has also lead to 
identify the putative substrate binding domains of PEPT1 and PEPT2, which reside in a 
region comprised of TMD 7, 8 and 9 with their in between loops (Fei et al., 1998).  
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Bolger and coworkers have demonstrated that computer simulation can be 
employed to study the structure-function relationship of transmembrane protein (Bolger 
et al., 1998).  Prediction by computer modeling and subsequent site-directed mutagenesis 
methods have identified that Tyr-167 in TMD5 , which is conserved in the peptide 
transporters from bacteria, fungi, yeast, plant, rabbit and human,  plays an essential role 
in hPEPT1 function, not the steady-state protein level or trafficking of the transporter to 
the plasma membrane (Yeung et al., 1998). 
With substituted cysteine accessibility method (SCAM), it was feasible to 
evaluate the relative orientation, functional importance, and solvent accessibility of a 
specific alpha-helical transmembrane segment of hPEPT1.  It has been demonstrated that 
both TMD5 and TMD7 form part of substrate translocation pathway (Kulkarni et al., 
2003a; Kulkarni et al., 2003b).  For TMD5, the extracellular half of the transmembrane 
seems to form a classical amphipathic alpha helix and the cytoplasmic half of the 
transmembrane seems to be highly solvent accessible.  Tyr-167, Asn-171, and Ser-174 in 
TMD5 might play  a role in substrate binding, since cysteine mutation of these residues 
were not tolerated (Kulkarni et al., 2003a).  TMD7 seems to be relatively solvent 
accessible along most of its length, and its cytoplasmic half is more so.  It was suggested 
that the extracellular end of TMD7 may shift following substrate binding, providing the 
basis for channel opening and substrate translocation.  Phe-293, Leu-296, and Phe-297 in 
TMD7 did not tolerate cysteine mutation, indicating that they might play a structural role 
in transporter function (Kulkarni et al., 2003b).  Moreover, TMD3 also appears to interact 
with other transmembrane domains (Links et al., 2007).   
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While it was suggested that N-terminal half of the PEPT1 and PEPT2 contain 
both the H
+
 binding and substrate recognition sites (Terada et al., 2000a), cytosolic C- 
terminal of the PEPT2 is demonstrated to be involved in apical membrane localization of 
the protein (Klapper et al., 2006).  Recently, it was revealed that Arg-282 in TMD7 and 
Asp-341 in TMD8 in hPEPT1 form salt bridge, and was proposed that this R282-D341 
charge pair might play a role in hPEPT1 translocation mechanism (Kulkarni et al., 2006).   
Until crystal structure of PEPT1 becomes available, 3D-structure of PEPT1 will 
be constantly refined by computer/homology modeling with the support of in vitro 
functional experiments.  
Substrate Structure Activity Relationship 
PEPT1 and PEPT2 substrate specificities have been intensively studied, but more 
focus on PEPT1 due to its importance in intestinal absorption of peptides/mimetics.  
Peptide transporters transport di- and tri-peptides, but not single amino acid or tetra-
peptide.  They also transport peptidomimetic compounds, such as β-lactam antibiotics 
(Tamai et al., 1997; Bretschneider et al., 1999), ACE inhibitors (Moore et al., 2000), 
renin inhibitors (Kramer et al., 1990; Hashimoto et al., 1994), anticancer drug bestatin 
(Saito and Inui, 1993), antiviral prodrug valacyclovir (Balimane et al., 1998; Ganapathy 
et al., 1998), and ω-amino fatty acids (Doring et al., 1998b).   Broad substrate specificity, 
expression in the intestine and kidney, ability to enhance the permeability of poorly 
absorbed drugs, and ability to prolong the half-life of drugs make peptide transporters 
very attractive target for oral drug delivery.  In order to design drugs that are targeted at 
peptide transporters, it is essential to understand their substrate structural requirements.  
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Conformation, size, charge, hydrophobicity, and side chain flexibility might affect 
substrate affinity for the peptide transporters.  Since three dimensional structures of 
peptide transporters are still not available, structure-affinity/transport relationship of 
compounds are usually carried out by inhibition and uptake assays.  Inhibition assays 
usually provide information on recognition and binding strength of ligand, but not the 
actual translocation of substrate.  Uptake studies and two electrode voltage clamp 
techniques allows the measurement of the actual translocation of a substrate across the 
biological membrane.   
PEPT2 is similar, but no identical to PEPT1 in terms of spectrum of substrates 
and structure requirement for substrate recognition.  Furthermore, most di- and tri-
peptides as well as peptidomimetic, such as valacyclovir and δ-aminolevulinic acid, show 
higher affinity to PEPT2 compared to PEPT1 regardless of their charges, sizes, and 
chemical structures (Terada et al., 2000b).  PEPT2 is assumed to have 10-15 times higher 
affinity to its substrates than PEPT1.  
Size:  Both PEPT1 and PEPT2 transport di- and tripeptides, but not single amino 
acids or tetra-peptides.  Size or molecular weight of peptides does not seem to be a 
limiting factor.  However cyclic dipeptides are not recognized by either  PEPT1 or 
PEPE2 (Terada et al., 2000b).  It was postulated that PEPT1 transport all possible 400 
dipeptides and 8000 tripeptides.  However, Vig and coworker recently have shown that 
not all dipeptides are substrate for PEPT1 transporter (Vig et al., 2006). 
Stereo-selectivity: Studies have demonstrated that both PEPT1 and PEPT2 
transporters selectively bind and transport the trans conformation of peptide derivatives 
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(Brandsch et al., 1998; Biegel et al., 2006).  PEPT1 also shows much higher affinity to 
di- and tri-peptides of L-isomers of amino acids then the D-isomers of amino acids (Li et 
al., 1998).  L-Val-L-Val showed highest affinity to PEPT1 followed by D-Val-L-Val, L-
Val-D-Val, and D-Val-D-Val in Caco-2 assay.  Val-Val-Val with 2 or 3 D-isomers of Val 
did not show any affinity to PEPT1 (Li et al., 1998).  
Charge:  Charged dipeptides appear to have a lower affinity compared to 
structurally similar zwitterionic dipeptides (Brandsch et al., 1999).  Vig and coworker 
have studied the effect of charge on PEPT1 function.  They found that dipeptides with 
one charged side chain have lower PEPT1 activation compared to dipeptides with neutral 
side chains, and it is further decreased if the both side chain are charged.  Dipeptides with 
acidic side chains at both positions were poor substrate for PEPT1.  Furthermore, 
dipeptides with basic side chains at both positions were not transported by PEPT1.  Arg-
Arg, Arg-Lys, Lys-Arg, Lys-Lys are not substrates for PEPT1 transporter.  Effect of 
charged amino acid in PEPT1 activation can be summarized as neutral-neutral > charged-
neutral ~ neutral-charged > acidic-acidic > basic-basic (Vig et al., 2006).  This is the first 
finding that not all di- and tri-peptides are substrates for PEPT1, and dipeptides with both 
positively charged amino acids are not transported by PEPT1 transporter.  
Peptide Bond:  Peptide bond is not an essential structural requirement for the 
recognition of a substrate either by PEPT1 or PEPT2 (Brandsch et al., 1998; Doring et 
al., 1998a; Doring et al., 1998b; Ganapathy et al., 1998).  Modification of dipeptides, by 
replacing the peptide bond by ketomethylene (Doring et al., 1998a) or thioxo and 
replacement of peptide carbonyl oxygen with sulfur (Brandsch et al., 1998), still retained 
their  affinity for PEPT1.  ω- amino fatty acids with more than four backbone units  are 
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translocated by PEPT1 without significant loss in affinity, further supporting that peptide 
bond is not essential for recognition by PEPT1 transporter (Doring et al., 1998b).  
Carbonyl group in small peptide/mimetic is an essential requirement for transport by 
PEPT1 (Schoenmakers et al., 1999).  Peptidomimetic analog without carbonyl group, 
though do not get transported by PEPT1, still have affinity for PEPT1 shown by 
inhibition studies (Schoenmakers et al., 1999).  
Terminal Group:  N-terminal amine and C-terminal carboxyl groups are not 
absolutely required.  Peptidomimetics without α-amino groups such as captopril, 
enalapril, and ceftubuten are transported by PEPT1.  However, modification of α-amino 
group seems to reduce the affinity for both PEPT1 and PEPT2 (Terada et al., 2000b).  
Methylation or acetylation on carboxyl group of dipeptides strongly reduced dipeptides’ 
affinity for PEPT1, suggesting that negatively charged carboxyl group may be essential 
for active transport of PEPT1 (Swaan and Tukker, 1997).  However, some studies also 
have shown that modification of C-terminal of Phe-Tyr to amide still retains its affinity to 
PEPT1 (Meredith et al., 2000).  Together, these studies suggest that C-terminal carboxyl 
group is not absolutely essential for transport; however, modification of it might reduce 
its affinity to PEPT1.  β-lactam antibiotic without an α-amino group has lower affinity to 
PEPT1 than β-lactam with an α-amino group.  
Side chain:  Hydrophobicity of the side chain seems to be a major determinant in 
affinity of a substrate.  Amino acids with more hydrophobic side chains are preferred 
over hydrophilic side chains by both PEPT1 and PEPT2 (Brandsch et al., 1999; Tateoka 
et al., 2001; Knutter et al., 2004; Biegel et al., 2006).  
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A summary of structural requirement for PEPT1 is illustrated in Figure 2.1.  Until 
three-dimensional structures of the peptide transporters are available, the current model 
will be refined by trial and error.  Nonetheless, the current structure-affinity relationship 
model might help the rational design of drug and prodrug targeted at peptide transporters.  
Mechanism of POT-Mediated Transport 
Both PEPT1 and PEPT2 use H
+
 concentration gradient and negative inside 
membrane potential as the driving force for translocating the peptides/mimetics across 














 ATPase, located in the basolateral membrane, maintains an inside negative 
membrane potential and Na
+
 concentration gradient across plasma membrane.  This 
generated Na
+




 exchanger located in the 
brush-border membrane to generate and maintains an H
+
 concentration gradient across 
cell membrane.  The created inward H
+
 electrochemical gradient drives the tertiary active 
transport of oligopeptides across the plasma membrane (Figure 2.2).  The H
+
 gradient 
stimulate the activity of PEPT1 and PEPT2 by increasing their transport rate without 
affecting their substrate affinity (Brandsch et al., 1997). 
Even though PEPT1 and PEPT2 have similar substrate specificities, they have 
different substrate affinities and mechanisms of transport.  Transports by both PEPT1 and 
PEPT2 are always electrogenic irrespective of the substrate’s net charge, and thus proton 
to substrate ratio differs based on the net charge of substrate.  For PEPT1, total charge 
(substrate plus proton) of +1 is required for transport of each peptide/mimetic.  Therefore, 
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for neutral and cationic dipeptides, the proton to substrate stoichiometric ratio is 1:1.  
Anionic dipeptides are transported both in their neutral forms at proton to substrate ratio 
of 1:1 and in their charged forms at ratio of 2:1 where one extra proton is required to 
quench the negative charge of the anionic dipeptides (Steel et al., 1997; Kottra et al., 
2002).  Cationic dipeptides are transported preferentially in their deprotonated neutral 
forms, also in their charged forms in lesser extent.  In contrast,  PEPT2 stoichiometry is 
+2 charge for each peptide being transported (Chen et al., 1999).  For neutral substrates, 
the proton to substrate ratio is 2:1.  In cases of anionic substrates, one extra proton is 
required to quench the negative charge resulting in proton to substrate ratio of 3:1 and 
charge to substrate ratio of 2:1.  For cationic substrate, the charge to substrate ratio is 2.4 
where they get transported either in its deprotonated (neutral) or its positively charged 
form (Chen et al., 1999).  In all cases, charged molecules present different binding 
affinity based on extracellular pH.  Affinity of anionic substrates increases substantially 
by decreasing the pH, whereas cationic dipeptides exhibit higher affinity in neutral or 
slightly alkaline extracellular pH.  However, proton binding to the transporter becomes 
limiting factor for efficient transport at more alkaline pH (Amasheh et al., 1997).  In 
general, the zwitterionic substrates that do not carry a net charge have preferential 
binding and transport by peptide transporters over charged substrates.  
Electrophysiological analysis of pre-steady state  current have demonstrated that 
H
+
 and substrates bind to PEPT1 in orderly fashion;  H
+
 binds to PEPT1 first followed by 
a change in substrate binding affinity, substrate binding, and then the simultaneous 
transport of the substrate and H
+
 together (Mackenzie et al., 1996).  In similar fashion, 
one H
+
 binds to the PEPT2 prior to the substrate binding (Chen et al., 1999).  Giant 
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patch-clamp experiments demonstrated that PEPT1 can transport dipeptides 
bidirectionally in an electrogenic and proton-coupled symport mode.  Under the normal 
physiological conditions, such as negative inside membrane potential, the external 
binding site shows higher substrate affinity than the internal binding site, allowing the 
substrate to be released into the cytosol.  However, under certain conditions such as low 
membrane voltage or absence of pH gradient, PEPT1 may even act as an electrogenic 
dipeptides-proton efflux symport (Kottra and Daniel, 2001).  
 
 INTESTINAL PEPTIDE ABSORPTION 
Structure of Small Intestine  
Most digestion and absorption of food take place in the small intestine, which 
consists of duodenum, jejunum, and ileum.  Structure of the small intestine is specially 
adopted for its absorptive function.  Its length provides a large surface area for 
absorption, and which is further increased by its wall structure of villi and microvilli. 
Mucus of the intestine forms a series of villi.  The large number of villi 
significantly increases the surface area of the epithelium available for absorption and 
digestion.  The epithelium of the mucosa consists of simple columnar epithelium that 
contains absorptive cells known as enterocytes, goblet cells (secrets mucus), hormone 
producing cells, and Paneth cells.  The apical membrane of the absorptive cells has 
microvilli, which further increases the surface area of epithelium.  In addition to villi and 
microvilli, the third feature of the intestine that further increases its surface area is the 
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circular folds.  These folds enhance the absorption by causing chime to spiral, rather than 
to move in a straight line as it passes through the small intestine.  Since the folds and villi 
decreases in sizes in the ileum, most absorption take place in the duodenum and jejunum.  
The villi, microvilli and folds all together increase the absorptive surface area of the 
small intestine by 600 times.  
The mucosal wall of the small intestine is arranged into two distinct structures, 
villi and crypts.  Villi projects into the lumen covered mostly with mature absorptive 
enterocytes along with some mucus-secreting goblet cells.  Cells in villi only live for a 
few days, and are shed into the lumen to be digested and absorbed.  Therefore, the major 
function of villi is nutrition absorption.  Crypts are moat-like structure of the epithelium 
around the villi, and are lined mainly with younger epithelial cells, which are involved 
primarily in secretion.  Toward the base of the crypts, there are undifferentiated stem 
cells, which continuously divide and provide the source of all the epithelial cells in the 
crypts and on the villi.  Crypts also contain mucous-secreting goblet cell, different 
endocrine epithelial cells, and Paneth cells with large secretory granules.  The known 
functions of crypts include epithelial cell renewal and secretion of ions, water, exocrine, 
and endocrine. A complete turnover of intestinal epithelial is approximately every 3-7 
days (Erickson, 1995).  
Molecules passing from the bulk phase of the intestine to epithelial cell apex 
encounter two distinct regions, the unstirred aqueous layer and the acidic microclimate.  
The unstirred aqueous layer is known to be a significant barrier to the highly lipiphilic 
molecules.  However, water soluble molecules are not significantly impeded by this 
layer.  The thickness of the effective unstirred layer was estimated to be about 530 µm in 
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rat jejunum (Winne, 1976) and 630 µm in human jejunum (Read et al., 1977).  
Microclimate of the small intestine, the close vicinity of the external surface of brush 
border membrane, is significantly more acidic than in the bulk phase of luminal fluid, 
especially in proximal part of the small intestine.  This acidic microclimate is created by 
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exchangers are trapped by the negatively charged mucopolysaccaride side chain.  Thus, 
mucus impedes the free diffusion of hydrogen ion into the bulk phase and maintains the 





 exchanger on the apical side of epithelium (Shiau et al., 1985; Shimada, 
1987).  
Bulk phase pH in rat and human jejunum fluid is reported to be about 6.5 and 7.1 
respectively (Weinstein et al., 1938; Steffansen et al., 1999).  In human and animals, the 
microclimate pH was reported to be 5.5-6.0 (Lucas et al., 1975; Said et al., 1986).  Since 
the intracellular pH in enterocytes is approximately 7.0-7.2 (Kurtin and Charney, 1984), 
there is a significant H
+
 electrochemical gradient across the plasma membrane to drive 
the uphill transport of small peptides via PEPT1 into enterocytes.  Within the 
microclimate or surface of epithelium, the upper part of villus is slightly more acidic than 
the base or crypts in duodenum and jejunum, and no gradient was observed in ileum 
(Daniel et al., 1989).  This pH difference could be attributed to H
+
 secretion from mature 
enterocytes located on the villus (Daniel et al., 1989). 
Microclimate pH can be altered by glucose and sodium content, but not 
significantly by pH of the bulk phase (Lucas et al., 1980; Hogerle and Winne, 1983; 
 24 
Shimada, 1987).  The microclimate pH is in isohydric with the bulk phase pH when the 
later is below 5.0.  The microclimate is more acidic than the bulk phase if the later is 
greater than 5.0.  When the pH of the bulk phase changes from 5.5 to 8.5, there is only a 
very minor change in the surface microclimate pH, roughly from 5.5 to 6.2.  As the 
glucose concentration in the bulk phase drops from 10 mM to 2 mM, the surface pH 
increases significantly.  It also increases when the concentration of sodium ion decreases 
in the bulk phase, and this change is more pronounce in the jejunum than the distal ileum 
(Lucas et al., 1980; Shimada, 1987).  
Protein Digestion 
Protein is an important part of our daily diet.  A typical western diet usually 
contains 70-100 g protein per day.  In addition to the dietary protein, saliva and 
gastrointestinal tract also secret a significant amount of protein (~35 g/day) (Ganapathy et 
al., 2006).  Of this total protein, about 95-98% is completely digested and absorbed in a 
normal individual (Erickson, 1995).  In gastrointestinal lumen, the proteins are converted 
into large peptides by gastric and pancreatic proteases, which subsequently undergo 
further hydrolysis by various peptidases on brush border membrane of intestinal 
epithelium into small peptides (80%) and free amino acids (20%) (Ganapathy et al., 
2006).  The final end products of protein digestion are absorbed into the enterocytes 
predominately in the form of di- and tripeptides as supposed to free amino acids 
(Matthews, 1975).  Once inside the enterocytes, the majority of the di- and tripeptides 
undergo further hydrolysis into their constituent amino acids by cytoplasmic peptidases 
and exit the epithelial cells via different basolateral amino acid transporters.  A small 
amount of small peptides that are resistant to cytoplasmic peptidases exit the enterocytes 
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intact across the basolateral membrane through a basolateral peptide transporter that still 
yet to be cloned (Terada et al., 1999) (Figure 2.3).  Furthermore, there are regional 
differences in small intestinal epithelium in respect to their absorptive capacities for free 
amino acids and small peptides.  While the proximal small intestine has a greater 
absorption capacity for small peptides compared to the distal small intestine, in contract, 
the distal intestine has a greater absorptive capacity for amino acids compared to the 
proximal small intestine (Matthews et al., 1971).  In addition, the activities of  brush 
border membrane peptidase are much higher in the ileal than in the jejunum (Silk et al., 
1976),  implying an increase in rate of appearance for single amino acids as the luminal 
content move along the intestine while concentration of small peptides decreases.  It was 
suggested that transporting 2 or 3 amino acids by PEPT1 in a form a small peptide 
requires the same amount of energy required to transport a single free amino acids 
(Daniel, 2004).  In addition, it was demonstrated that it was faster to transport amino 
acids in small peptide form in terms of uptake per unit time compared to transporting 
their constituent amino acids in the free forms (Gilbert et al., 2008).  
Peptide Transporters in Intestine 
For a long time, it was commonly believed that only amino acids are absorbed by 
the intestinal epithelial cells.  But, it was later found that the end products of protein meal 
are not exclusively free amino acids, rather a mixture of free amino acids and small 
peptides (Matthews, 1975).  The intestinal epithelium has separate mechanisms for their 
absorption from the intestinal lumen.  There are regional differences in the absorptive 
capacities for free amino acids and small peptides.  The absorption capacity for small 
peptides is greater in the proximal small intestine than the distal small intestine, whereas 
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the absorptive capacity for amino acid is greater in the distal small intestine than in the 
proximal small intestine.    
Di- and tri-peptides are carried into the mucosal cells via H
+
 dependent peptide 
transporters.  Once inside the epithelium cells, they have two possible fates.  Some 
peptides get digested into their constituent amino acids by cytoplasmic peptidase, 
followed by transportation across the basolateral membrane into the blood circulation.  
Undigested di- and tri-peptides are transported intact across the basolateral membrane.  
Some larger peptides are absorbed by transcytosis after binding to a receptor on the 
luminal surface of the epithelium.  
The primary known peptide transporter in the small intestine is PEPT1.  However, 
recently, some other peptide transporters are also reported to be expressed along the 
intestine; transcripts of PHT1, PHT2, and HPT1 were found in the intestine (small 
intestine and colon) (Herrera-Ruiz et al., 2001).   PHT1 protein was localized at villous 
epithelium (Bhardwaj et al., 2006).  Nonetheless, these findings do not rule out the 
possible existence of other peptide transporters in the small intestine.  
Basolateral Peptide Transporters in Intestine 
When peptides are taken up by the intestinal enterocytes via PEPT1, they diffuse 
through the cytoplasm and exit into the portal blood across the basolateral membrane as 
intact dipeptides or as metabolized amino acids constituents.  Until 1990, it was 
commonly believed that only free amino acids entered portal blood from intestinal 
epithelial cells (Matthews, 1975).  However, some recent studies have established that 
~50% of the amino acids circulating in the plasma are peptide bond, and majority of 
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which are in di- and tri-peptides forms (Seal and Parker, 1991).  Furthermore, Gardner et 
al have also reported that about 10% of the amino nitrogen entering the mesenteric blood 
during absorption of a casein digest in vivo was in the form of small peptides (Gardner et 
al., 1983).  These findings suggest the existence of basolateral peptide transporters for 
exit mechanism of dipeptides from enterocytes.    
Studies have indicated that the apical and basolateral sides of human intestinal 
cell line, Caco-2, have distinct peptide transporters which are active and facilitative 
transporter systems, respectively (Terada et al., 1999).  This basolateral peptide 
transporter in Caco-2 cells, like PEPT1,  has been associated with the translocation of 
peptide like drugs, such as bestatin (Saito and Inui, 1993),  cephalosporins (Inui et al., 
1992; Matsumoto et al., 1994) as well as nonpeptidic drugs like  δ-aminolevulinic acid 
(δ-ALA) and valacyclovir (Irie et al., 2001) in addition to transporting small peptides 
(Terada et al., 1999).  The basolateral peptide transporter was also demonstrated to be 
pH-independent, incapable of uphill transport (Saito and Inui, 1993) and relatively low 
affinity compared to the apical dipeptides transporter, PEPT1.  However, there have been 
few contradicting reports suggesting that basolateral peptide transporter is H
+
 dependent 
(Dyer et al., 1990; Thwaites et al., 1993).  The kinetic analyses also verified that a single 
facilitative peptide transporter was involved in the basolateral transport of small 
peptides/mimetics in Caco-2 cells.  Directional studies, influx from basolateral to cytosol 
and efflux in opposite direction, have also revealed that this basolateral peptide 
transporter is symmetric in terms of substrate specificity,  pH independence for peptide 
transport, and asymmetric in substrate affinity (Irie et al., 2004).  Shepherd et al has 
suggested a novel 112 kDa protein with no obvious similarity to PEPT1 as a candidate 
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for basolateral peptide transporters in rat jejunum (Shepherd et al., 2002).  Taken 
together, PEPT1 absorbs substrates from the intestinal luminal to the enterocytes on the 
apical side, and this basolateral peptide transporter mediates the extrusion of those 
substrates from the cytosol to the blood stream.  Together, PEPT1 and basolateral peptide 
transporter facilitate the efficient intestinal absorption of small peptides and peptide like 
drugs.   
 
PEPT1 TRANSPORTER 
Polymorphism and Splice Variants of PEPT1 
Genetic variations in drug receptors, metabolizing enzymes, and transporters are 
some of the sources for inter-individual variability in the drug effect and disposition.  
Since PEPT1 is involved in the carrier mediated uptake of various peptide-like drugs 
such as β-lactam antibiotics, ACE inhibitors, and antiviral nucleosides L-valacyclovir, 
polymorphism in PEPT1 could result in variation in therapeutic efficacy of those drugs 
among different patients.  Studies have shown that valacyclovir, a known PEPT1 
substrate, have larger inter-individual variability than intra-individual variability in 
intestinal absorption, suggesting the presence of a genetic variations in PEPT1 (Phan et 
al., 2003). 
Some studies suggest that two human PEPT1 gene polymorphism variants might 
be involved in susceptibility to bipolar disease (Maheshwari et al., 2002).  However, 
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further investigation is needed to confirm whether or not PEPT1 is causative for this 
disease.   
Recently, by screening a DNA polymorphism discovery panel of 44 ethnically 
diverse individuals, nine nonsynonymous coding-region single-nucleotide 
polymorphisms (cSNPs) in human PEPT1 have been identified (Zhang et al., 2004).  
Among those variants, only one variant, P586L, had a reduced protein expression 
(western blot), lower plasma membrane expression (immunocytochemical analysis) and 
reduced transport capacity while maintained a similar affinity to GlySar and other drug 
substrate as the other variants.  This finding suggests that P586 may has a role in 
translation, degradation and/or membrane insertion of PEPT1 in the plasma membrane 
(Zhang et al., 2004).  This is consistent with other studies, where it was suggested that the 
C-terminal of the peptide transporters might be involved in membrane localization 
(Klapper et al., 2006).  
A similar study has been performed in Dr. Sadee’s lab, where all 23 exons and 
adjoining intronic regions of PEPT1 were screened in collection of 247 ethnically diverse 
subjects (Anderle et al., 2006).  Of 39 identified variants, 18 are located at exons, and of 
which only nine are nonsynonymous.  Among 9 nonsynonymous SNPs, only one low 
frequency F28Y variant has an altered affinity to dipeptides without significant change in 
protein expression level from wild-type.  Even though P586L and F28Y have a 
significant effect on the function of PEPT1, they both are low frequency variants, thus, 
would have a minimal impact on oral absorption of PEPT1 drug substrates.  The two 
common SNPs in hPEPT1 S117N and G419A were found to maintain the same kinetic 
properties as the wild-type suggesting that the both variants are not likely to have major 
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effect on oral drug absorption (Sala-Rabanal et al., 2006).  Taken together, PEPT1 seems 
to have low genetic variability.  Its polymorphisms are not expected to be a major factor 
in inter-individual variability in oral absorption of PEPT1 substrates.    
Alternating splicing in hPEPT1 RNA expression leads to the formation of a splice 
variant hPEPT-RF, which modulates the transport activity of hPEPT1 by serving as a pH-
sensing regulatory factor (Saito et al., 1997; Urtti et al., 2001).  While hPEPT1 has 23 
exons, its splice variant hPEPT1-RF has six.  It shares three exons completely and two 
exons partially with hPEPT1.  When expressed alone, the slice variant hPEPT1-RF lacks 
the peptide transport activity.  
Regulation of PEPT1 
Changes in functional characteristic and / or expression level of PEPT1 
transporter in the small intestine could be possible sources for intra- and inter-individual 
variability of oral bioavailability of drugs.   Such correlation between variation in PEPT1 
expression level (both mRNA and protein level) and absorption permeability of peptide-
like drugs in small intestine of rat has been established (Chu et al., 2001; Naruhashi et al., 
2002).  Studies have shown that the expression of PEPT1 transporter is regulated by 
diets, hormones, growth factors, diurnal rhythm, drugs, and disease states.  The 
mechanisms responsible for these changes in expression level could be attributed to the 
alteration in PEPT1 gene transcription, intracellular trafficking of PEPT1 protein, or 
some other unidentified mechanisms.  
PEPT1 has number of potential N-glycosylation sites and protein kinase 
recognition sites, indicating that the transporter can be regulated by reversible 
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phosphorylation.  Studies on Caco-2 has revealed that activation of protein kinase C 
(PKC)  decreases the maximal transport rate (Vmax) of the PEPT1 without significant 
change in affinity (Km ) (Brandsch et al., 1994).  
One potential regulator of expression of any transporter is its own substrates.   
Studies have demonstrated that treatment of Caco-2 with dipeptides have increased both 
cellular PEPT1 mRNA and the membrane protein expression without significant change 
in Km value.  The mechanism responsible for this change appears to be the regulation of 
expression gene encoding the PEPT1 (Thamotharan et al., 1998; Walker et al., 1998).  
Theses in vitro results were confirmed with in vivo studies by feeding the rats with 
varying amount of protein (Erickson et al., 1995; Shiraga et al., 1999).  The results 
showed that high protein meal induces an increase in PEPT1 mRNA which will lead to 
an increase in the population of PEPT1 transporter (Erickson et al., 1995; Shiraga et al., 
1999).     
Among different hormones, insulin, epidermal growth factor (EFG), leptin, and 
thyroid hormones have shown to affect the expression of PEPT1 transporter.  When 
insulin was added to Caco-2 medium at physiological concentration, the uptake of 
dipeptides in Caco-2 was stimulated; The mechanism that accounts for this increased 
dipeptides uptake appears to be the increased population of membrane PEPT1 induced by 
the increased translocation of PEPT1 from preformed cytoplasmic pool (Thamotharan et 
al., 1999b; Nielsen et al., 2003; Watanabe et al., 2004).  EGF had an opposite effect on 
PEPT1 functional expression based on its duration of exposure.  In long-term (> 5 days) 
treatment of basolateral membrane of Caco-2 with EGF, there was a decrease in PEPT1 
protein expression as a result of a decreased PEPT1 mRNA, which leads to a decrease in 
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dipeptides uptake (Nielsen et al., 2001).  However, when the basolateral membrane of 
Caco-2 was treated with EGF for only short period (< 1h) of time, there was a dose 
dependent increase in apical uptake of dipeptides (Nielsen et al., 2003).  The kinetic 
analysis revealed that there is an increase in Vmax having no significant changes in Km and 
PEPT1 mRNA level (Nielsen et al., 2003).  The actual mechanism of the increased 
PEPT1 function remains to be elucidated.  Short-term apical treatment of Caco-2 with 
leptin and intrajejunal leptin treatment of rat small intestine (mimicking gastric release of 
leptin) have increased the uptake of dipeptides, and the mechanism appears to be similar 
to the effect of insulin, which is an increased trafficking of PEPT1 from cytosolic pool to 
the apical membrane, without altering PEPT1 mRNA level (Buyse et al., 2001).  When 
chronic hyperleptimia was induced in rats, interestingly, PEPT1 mRNA, protein, and 
dipeptide uptake all seem to increase (Hindlet et al., 2007).  The molecular mechanism 
responsible for these changes appears to be that leptin regulates PEPT1 at both 
transcriptional level via MAPK and at translational level via ribosomal protein S6 
activation (Hindlet et al., 2009).    
Treatment of Caco-2 cells with thyroid hormone has induced a decrease in the 
PEPT1 activity due to a decreased transcription and/or a decreased  stability of PEPT1 
mRNA (Ashida et al., 2002).  Regulation of PEPT1 by thyroid hormone was also 
confirmed with in vivo studies (Ashida et al., 2004).  Hyperthyroidism in rat has resulted 
in a decrease in PEPT1 activity caused by the decreased PEPT1 mRNA and protein 
expression in the small intestine (Ashida et al., 2004).  Hypothyroidism in rats have also 
lead to an increase in renal PEPT1 mRNA (Lu and Klaassen, 2006). 
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Pathological conditions, especially in GI tract, have also shown to affect the 
PEPT1 functional activity.  One of the common nutritional conditions is a brief fasting 
when the patient is severely ill.  Fasting, short or prolonged, increases the PEPT1 mRNA 
expression level, resulting in an increased PEPT1 transporter protein in the brush border 
membrane of the small intestine (Ogihara et al., 1999; Thamotharan et al., 1999a; Ihara et 
al., 2000; Naruhashi et al., 2002), resulting altered pharmacokinetic of PEPT1 substrates 
(Pan et al., 2003).  Mechanistic studies have suggested that this fasting induced intestinal 
PEPT1 expression is mediated by a nuclear receptor, peroxisome proliferator-activated 
receptor α (PPARα) (Shimakura et al., 2006).  Uncontrolled diabetic rats have an 
increased PEPT1 activity due to the increased stability of PEPT1 mRNA without any 
changes in transcriptional rate both in the small intestine and kidney (Gangopadhyay et 
al., 2002).  Intestinal resection in patients induces an increase on mRNA and protein level 
of PEPT1 in colon (Ziegler et al., 2002).  Expression of PEPT1 was observed from colon 
of patients with short bowel syndrome (Ziegler et al., 2002), inflammatory bowel 
diseases such as ulcerative colitis and Crohn’s disease, but not in normal human colon; 
however, the mechanism responsible for this up-regulation of PEPT1 in colon still 
remains unclear (Merlin et al., 2001).  There is a transcriptional up-regulation of PEPT1 
during acute infection with Cryptosporidium Parvum, a common cause of diarrheal 
disease, (Barbot et al., 2003), although the expression of PEPT1 protein remains the same 
(Marquet et al., 2007).  In contrast, there is a decrease in the expression of PEPT1 in 
jejunal epithelial cells when rats are infected with Nippostrongylus brasiliensis (Sekikawa 
et al., 2003). 
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There are also a number of pharmacological agents that are known to affect the 
PEPT1 expression.  Studies have suggested that 5-fluorouracil, an anticancer drug that 
has a deleterious effect on intestinal mucosa, increases the gene expression of PEPT1 
(Tanaka et al., 1998; Inoue et al., 2005).  Clonidine, an agonist for α2-adrenergic 
receptor, has shown to increase the translocation of preformed cytosolic PEPT1 to apical 
membrane of Caco-2 cells, resulting in an increased transport activity of PEPT1 (Berlioz 
et al., 2000), in similar mechanism to insulin (Thamotharan et al., 1999b) and leptin 
(Buyse et al., 2001).  Pentazocine, a σ-ligand receptor, increases the PEPT1 mRNA in 
Caco-2 cell, and thus, results in an increased population of PEPT1 transporter protein in 
the plasma membrane leading to an increase in peptide transporter activity (Fujita et al., 
1999).  Immunosuppressive agent such as tacrolimus and cyclosporine reduce Vmax of 
GlySar uptake on Caco-2 without any effect on Km (Motohashi et al., 2001).  
In addition to regulation by factors mentioned above, PEPT1 is also regulated by 
diurnal rhythm (Pan et al., 2002) and this diurnal rhythmic regulation closely is related to 
feeding schedule (Pan et al., 2003; Pan et al., 2004).  Mechanistic studies have suggested 
that clock controlled gene, albumin D site-binding protein (DBP) plays a major role in 
this diurnal rhythmic regulation of PEPT1 (Saito et al., 2008). 
A thorough understanding of the regulation of PEPT1 transporter will have an 
implication in nutrition and drug therapy, and may offer explanations to some of the 
intra- and inter-individual variability in drug responses.  
Prodrug Approach Using PEPT1 Transporter 
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PEPT1 is a very attractive target for the development of prodrug due to its broad 
substrate specificity and high capacity.  A drug with low oral bioavailability can be 
converted into a prodrug via attachment of a moiety, which can be recognized by PEPT1 
transporter in the small intestine.  Following the membrane transport, the prodrug can be 
converted back to its parent drug by hydrolysis in epithelial cells, blood, or liver.  PEPT1-
targeted prodrugs have a great structural flexibility, and can be either peptidyl or 
nonpeptidyl prodrugs.  Thus far, there are increasing numbers of prodrugs that are 
targeted at PEPT1.  Examples of peptidyl prodrug of PEPT1 include prodrug of α-
methyldopa, a poorly absorbed antihypersensitive agent, to α-methyldopa-Phe, α-
methyldopa-Pro (Hu et al., 1989), and p-glu-L-dopa-pro (Bai, 1995).  The Prodrugs of α-
methyldopa have a significantly increased intestinal permeability and an increased oral 
bioavailability compared to their parent drug.  Nonpeptidyl prodrug such as L-
valacyclovir, an amino acid ester prodrug of antiviral drug acyclovir, has been shown to 
be a substrate for PEPT1 in intestine.  Through this mechanism, L-valacyclovir improved 
the oral bioavailability of acyclovir 3-5 times (Balimane et al., 1998; Ganapathy et al., 
1998).  L-valine ester prodrug of ganciclovir, valganciclovir, is also shown to be 
transported by PEPT1 (Sugawara et al., 2000).  Therefore, PEPT1-targeted prodrug 
therapy is a promising strategy to improve the intestinal absorption and thus the oral 
bioavailability of poorly absorbed drugs.  
Experimental Models to Study PEPT1 
Due to the importance of PEPT1 transporter in the intestinal absorption of 
peptides/mimetics, PEPT1 has been studied extensively in various experimental 
conditions.  Most of the previous studies were in vitro models that lacked intact blood 
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supplies such as PEPT1 expression in Xenopus laevis oocytes (Fei et al., 1994; Liang et 
al., 1995; Fei et al., 2000) and in various cell lines, such as LLC-PK1, CHO, Hela, and 
MDCK cells, by transient or stable transfection.  Other in vitro models that did not 
differentiate the effect of PEPT1 from other possible peptide transporters include Caco-2 
cell line, brush border membrane vesicle, and Ussing chamber with the small intestine.  
In-situ rat intestinal perfusion has also been utilized in PEPT1 studies.  Although this 
model has an intact blood supply, it does not differentiate PEPT1 transporter from other 
possible peptide transporters in the small intestine.  
 
PHT TRANSPORTERS 
Functional Characteristic of PHT Transporter 
Peptide-histidine transporter 1 (PHT1) was first cloned from the rat brain 
(Yamashita et al., 1997) cDNA library.  Rat PHT1 is predicted to have 572 amino acid 
residues with estimated core molecular mass of 64.9 kDa.  Recently, the human 
orthologue of PHT1 was also cloned and characterized (Bhardwaj et al., 2006).  The 
putative hPHT1 is 86.5% identical to rPHT1 and 48.4% identical to rPHT2.  The human 
PHT1 is predicted to have 577 amino acids with estimated molecular weight of 62 kDa.  
The structural analysis of hPHT1 and rPHT1 suggest that PHT1 protein contains 12 
transmembrane domains with both N- and C- terminals facing the cytosolic side.  
Functional characteristics of rPHT1 and hPHT1 were evaluated by expression in Xenopus 
laevis oocytes and transient transfection of COS-7 cells, respectively.  Both studies 
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demonstrated that PHT1 transports histidine and carnosine with high affinity in a proton-
dependent and Na
+
 concentration gradient independent manner.  The transport of 
histidine by PHT1 was inhibited by various dipeptides and tripeptides, but not single 
amino acids, suggesting that PHT1 also transports di- and tripeptides (Yamashita et al., 
1997; Bhardwaj et al., 2006).  One interesting finding was that of COS-7 cells transfected 
with hPHT1 did not show much affinity for GlySar (Bhardwaj et al., 2006).  Peptide-
histidine transporter 2 (PHT2) was cloned from rat brain cDNA library (Sakata et al., 
2001) and rPHT2 is predicted to encode a protein of 582 amino acid. 
PHT1 is distributed in various tissues.  The PHT1 mRNA was found in brain, 
eyes, skeletal muscle, kidney, liver, heart, lung, spleen, colon, thymus, and throughout 
the GI tract (Yamashita et al., 1997; Botka et al., 2000; Herrera-Ruiz et al., 2001; 
Ocheltree et al., 2003).  In the GI tract, the hPHT1 protein was detected in the stomach, 
duodenum, jejunum, ileum, and colon.  Immunohistochemical analyses demonstrated that 
PHT1 is localized at villous epithelium of small intestine (Bhardwaj et al., 2006).  PHT2 
mRNA is mostly found in lymphatic system, lung, spleen, thymus, and faintly in brain, 
liver, adrenal gland, heart, and the GI tract (Herrera-Ruiz et al., 2001; Sakata et al., 
2001).  Unlike other POT members, PHT2 is found in lysosome rather than plasma 
membrane which was demonstrated by light and electron-microscopic analysis (Sakata et 
al., 2001). 
The functional roles of PHT1 and PHT2 have been evaluated in several tissues 
including brain and eyes.  In evaluation of functional activity of PHT1 and PHT2 in 
brain, synaptosomes from rat cerebral cortex were prepared, and the presence of PHT1 
and PHT2 mRNA were confirmed by RT-PCR (Fujita et al., 2004).  They have found that 
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the uptake of histidine into synaptosomes was independent of a transmembrane pH 
gradient and was not inhibited by GlySar, suggesting that the uptake of histidine was not 
mediated by PHT1 and PHT2, but rather by various kinds of amino acid transporters.  
Furthermore, the uptake of GlySar into synaptosomes was not inhibited by the presence 
histidine, confirming that PHT1 and PHT2 were not responsible for the uptake of GlySar 
into synaptosomes from the cerebral cortex of rat (Fujita et al., 2004).  The functional 
activity of PHT1  and PHT2 was also investigated in rat neonatal astrocytes (Xiang et al., 
2006).  The uptake of carnosine, a known substrate for both PEPT2 and PHT1, was not 
affected by L-histidine, a PHT1 and PHT2 substrate, suggesting that PHT1 and PHT2 
were not functionally active in astrocytes (Xiang et al., 2006).  The functional activity of 
PHT1 was also investigated in retina (Ocheltree et al., 2003).  PHT1 mRNA was 
expressed in retinal pigment epithelium (RPE), a human retinal epithelium cell line 
ARPE-19, and neural retina (Ocheltree et al., 2003).  However, the uptake of GlySar in 
retinal epithelium cell line ARPE-19 was not inhibited by the presence of 1 mM L-
histidine.  This suggests that, despite the presence of mRNA, PHT1 is not functionally 








Figure 2.1  Model of PEPT1 substrate-affinity/transport relationship.  The preferred 
configuration and important conformational features in PEPT1 transporter recognition is 
summarized.  PEPT1 and PEPT2 have very similar not identical structure requirement for 










Figure 2.2  Model of peptide/mimetics in a single epithelial cell in the intestine and 
kidney. The peptide transporters PEPT1 and PEPT2 are located at the brush border 
membrane. They transport small peptide/mimetics from the lumen into the cell. They are 
energized by H
+
 transmembrane gradient and negative membrane potential, which are 








exchangers. Once inside of the cell, the peptide/mimetics are either metabolized into 
amino acids/metabolites for use or export, or remain as intact. They exit the cell via 
basolateral amino acid transporters or basolateral peptide transporter accordingly. 










Figure 2.3  Schematic of protein digestion and absorption in the gastrointestinal tract.  
(Figure adopted from Ganapathy V, Gupta N, and Martindale RG.  Protein Digestion and 
Absorption.  In Physiology of the Gastrointestinal Tract, 4
th
 edition, Johnson LR (ed), 










Table 2.1  Molecular and Functional Features of POTs 
Features PEPT1 PEPT2 PHT1 PHT2 
Human gene name SLC15A1 SLC15A2 SLC15A4 SLC15A3 
Mammalian species Rabbit Human Rat Mouse Human Mouse Rat Rabbit Rat Human Rat 
Amino acids 707 708 710 709 729 729 729 729 572 577 582 
Protein Kinase A site 1 0 1 1 0 0 3 0 0 2 2 
Protein Kinase C site 1 2 1 1 5 2 3 4 11 11 4 
Glycosylation site 4 7 5 6 3 2  5 4 4 3 
Transmembrane domain 12 12 12 12 
Coupling ion Cotransport  /H+ Cotransport  /H+ Cotransport  /H+ Cotransport  /H+ 
Amino acid in substrate 2-3 2-3 2-3 2 
Transport of L-Histidine No No Yes Yes 
Substrate affinity Low High High ? 
Km value mM µM µM ? 
Stereoselectivity L > D L > D   
Amino acid identity 
between species 
81% human vs. rabbit 
83% human vs. rat 
83% human vs. mouse 
77% rat vs. rabbit 
82% human vs. mouse 
82% mouse vs. rabbit 
92% mouse vs. rat 
86.5 % human vs. rat  
Amino acid identity 
between POTs 
 ~ 50% PEPT2 vs. PEPT1 
 
17% PHT1 vs. PEPT1 
12% PHT1 vs. PEPT2 
49% PHT2 vs. PHT1 
22% PHT2 vs. PEPT1 
24% PHT2 vs. PEPT2 
 
References for Table 2.1 include: Fei et al., 1994; Liang et al., 1995; Liu et al., 1995; Saito et al., 1995; Boll et al., 1996; 
Miyamoto et al., 1996; Saito et al., 1996; Yamashita et al., 1997; Fei et al., 2000; Rubio-Aliaga et al., 2000; Sakata et al., 2001; 




Table 2.2  Tissue and Cellular Distribution of POTs 
POT 
isoform 
Tissue Species RNA Protein Localization  
PEPT1 Small 
intestine 
Rabbit, Human, Rat, 
Mouse 
Y Y Brush border of enterocytes 
 Kidney Rabbit, Human, Rat, 
Mouse 
Y Y Brush border membrane of epithelium cells of 
S1 segment of proximal tubule and lysosome 
 Liver Rabbit, Human Y  lysosome 
 Pancreas Human  Y Lysosome acinar cells 
 Placenta Human Y   
 Testis Rat Y   
 Ovary Mouse Y   
 Lung Mouse Y  Epithelial cells 
 Prostate Human Y   
 Bile duct  Y Y Apical membrane of cholangicytes 
PEPT2 Kidney Rat, Mouse, Rabbit Y Y Brush border membrane of epithelium cells of 
S2 and S3 segment of proximal tubule 
 Brain Rat Y Y astrocytes, subependymal cells, ependymal cells 
and epithelial cells of choroid plexus 
 Lung Rabbit, Rat Y Y Apical membrane of alveolar type II 
pneumocytes and bronchial epithelium and 
endothelium of small arteries 
 Liver Rabbit Y   
 Heart Rabbit Y   
 Mammary 
gland 
Rat Y Y  Epithelial cells of glands and ducts 
 Eye  Y  Retina epithelium  
PHT1 Brain Rat, Human Y   
 Eye Rat, Bovine, Human Y   
 Lung Rat Y   
 Spleen Rat Y   
 GI tract Rat Y   
 Skeletal 
muscle 
Human Y   
 Kidney Human Y   
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 Small 
intestine 
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 Adrenal glad Rat Y   
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 Small 
intestine 
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Human Y   
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intestine 
Human, Rat Y   
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Chapter 3  
 
TRANSPORT MECHANISMS OF CARNOSINE IN SKPT 
CELLS: CONTRIBUTION OF APICAL AND 
BASOLATERAL MEMBRANE TRANSPORTERS 
ABSTRACT 
Purpose.  The aim of this study was to investigate the transport properties of carnosine in 
kidney using SKPT cell cultures as a model of proximal tubular transport, and to isolate 
the functional activities of renal apical and basolateral transporters in this process.   
Methods.  The membrane transport kinetics of 10 µM [
3
H]carnosine was studied in 
SKPT cells as a function of time, pH, potential inhibitors and substrate concentration.  A 
cellular compartment model was constructed in which the influx, efflux and 
transepithelial clearances of carnosine were determined.  Peptide transporter expression 
was probed by RT-PCR.   
Results.  Carnosine uptake was 15-fold greater from the apical than basolateral surface of 
SKPT cells.  However, the apical-to-basolateral transepithelial transport of carnosine was 
severely rate-limited by its cellular efflux across the basolateral membrane.  The high-
affinity, proton-dependence, concentration-dependence and inhibitor specificity of 
carnosine supports the contention that PEPT2 is responsible for its apical uptake.  In 
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contrast, the basolateral transporter is saturable, inhibited by PEPT2 substrates but non-
concentrative, thereby, suggesting a facilitative carrier.   
Conclusions.  Carnosine is expected to have a substantial cellular accumulation in kidney 
but minimal tubular reabsorption in blood because of its high influx clearance across 
apical membranes by PEPT2 and very low efflux clearance across basolateral 
membranes.   
 




Proton-coupled oligopeptide transporters (POTs) are membrane proteins that 
translocate various small peptides and peptide-like drugs across the biological membrane 
via an inwardly-directed proton gradient and negative membrane potential.  At present, 
four members of the POT family, namely PEPT1, PEPT2, PHT1 and PHT2, have been 
identified in mammals (Herrera-Ruiz and Knipp, 2003; Daniel and Kottra, 2004).  POTs 
have significant physiological roles in the absorption and reabsorption of peptide-bound 
amino nitrogen as well as pharmacological roles in drug absorption and disposition (e.g., 
β-lactam antibiotics, angiotensin-converting enzyme inhibitors, renin inhibitors, bestatin 
and valacyclovir).  PEPT1, cloned from a rabbit small intestine cDNA library (Fei et al., 
1994), has been characterized as a high-capacity, low-affinity transporter.  In addition to 
its expression in apical membranes of S1 segments in proximal tubule (i.e., kidney 
cortex), PEPT1 is highly expressed in apical membranes of small intestine (Shen et al., 
1999; Groneberg et al., 2001).   PEPT2, cloned from a human kidney cDNA library (Liu 
et al., 1995), is a low-capacity, high-affinity transporter that is primarily localized in the 
brush border of S3 segments in proximal tubule (i.e., outer stripe of outer medullar) (Liu 
et al., 1995; Shen et al., 1999; Rubio-Aliaga et al., 2000), as well as in brain, choroid 
plexus, eye, lung and mammary gland (Groneberg et al., 2002).  In spite of the sequential 
expression of PEPT1 and PEPT2 in renal proximal tubules, studies have definitively 
shown that PEPT2 accounts for the vast majority of reabsorption for the model dipeptide 
glycylsarcosine (GlySar) and the β-lactam antibiotic cefadroxil in kidney (Takahashi et 
al., 1998; Inui et al., 2000; Ocheltree et al., 2005; Shen et al., 2007).   
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Two additional peptide transporters, PHT1 (Yamashita et al., 1997)  and PHT2 
(Sakata et al., 2001), have been cloned from a rat brain cDNA library.  Unlike PEPT1 and 
PEPT2, they transport a single amino acid, L-histidine, in addition to the proton-
stimulated transport of di/tripeptides.  While PHT1 mRNA is abundantly expressed in rat 
brain and eye, PHT2 mRNA is abundant in rat lung, spleen, thymus and immunocytes.  
Unlike other POT family members, PHT2 protein was found subcellularly in the 
lysosomes of transfected cell lines rather than in the plasma membrane, as demonstrated 
by light and electron-microscopic analyses (Sakata et al., 2001).  Compared to PEPT1 
and PEPT2, relatively little is known about PHT1 and PHT2 with respect to their 
physiological roles, substrate specificities, precise localization and directionality of 
transport.   
Functional studies have indicated the presence of distinct basolateral peptide 
transporters in the small intestine (Terada et al., 1999) and kidney (Terada et al., 2000).  
In this regard, the intestinal basolateral peptide transporter, expressed in the Caco-2 cells, 
was suggested as a facilitative efflux transporter that assists in the efficient absorption of 
small peptides/mimetics by mediating their extrusion from cell to blood (Terada et al., 
1999; Sawada et al., 2001; Irie et al., 2004).  In contrast, the renal basolateral peptide 
transporter, expressed in MDCK cells, was suggested as an influx transporter facilitating 
the clearance of small peptides/mimetics from the blood circulation (Sawada et al., 2001).  
Thus far, none of these basolateral peptide transporters have been cloned and, hence, they 
are not well characterized compared to current members of the POT family.   
Carnosine (β-alanyl-L-histidine) is a naturally-occurring dipeptide that is highly 
concentrated in skeletal muscle and brain.  Besides being an endogenous substrate, 
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carnosine is also taken exogenously as a dietary supplement for its antioxidant and free 
radical scavenging properties (Aruoma et al., 1989; Hartman et al., 1990).  In the body, 
carnosine prevents glycation and the cross-linking of proteins by deleterious aldehydes 
and ketones (Hipkiss et al., 1998), further protecting the cell against oxidative damage.  
The potential benefit of carnosine is limited by its susceptibility to hydrolysis by tissue 
and serum carnosinase, but not α-peptidase (Hipkiss, 1998), resulting in degradation to its 
constituent amino acids (i.e., β-alanine and L-histidine).  Pharmacologically, carnosine 
has some renoprotective effects including acting as a protective factor in diabetic 
nephropathy (Janssen et al., 2005) and preventing ischemia-induced renal injury (Fujii et 
al., 2003; Fujii et al., 2005; Kurata et al., 2006).  Carnosine is transported by all of the 
POTs (Yamashita et al., 1997; Sakata et al., 2001; Son et al., 2004; Teuscher et al., 2004; 
Bhardwaj et al., 2006).   
Even though carnosine has significant pharmacological importance in the kidney, 
the renal disposition of this dipeptide has not been elucidated.  Therefore, the aim of this 
study was to investigate the transport properties of carnosine in kidney using SKPT cell 
cultures as a model of proximal tubular transport, and to isolate the functional activities 
of renal apical and basolateral transporters in this process.   
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H]Carnosine (10 Ci/mmol) and [
14
C]D-mannitol (53 mCi/mmol) were 
purchased from Moravek Biochemicals (Brea, CA).  Primers for the PCR analyses were 
obtained from Invitrogen Life Technologies (Carlsbad, CA).  The epithelial cell line 
SKPT-0193 C1.2, established by SV40 transformation of isolated rat kidney proximal 
tubule cells, was kindly provided by Dr. Ulrich Hopfer (Case Western Reserve 
University, Cleveland, OH).  All other chemicals were from standard sources and were of 
the highest quality available.   
Cell Cultures 
SKPT cells were grown on 75 cm
2
 cell culture flasks and cultured in 1:1 DMEM 
(without glucose)/HAM’S F12 medium supplemented with 5% fetal bovine serum, 5 
μg/ml apotransferrin, 5 μg/ml insulin, 4 μg/ml dexamethasone, 10 ng/ml epidermal 
growth factor, 15 mM HEPES, 0.06% NaHCO3, 50 μM ascorbic acid, 20 nM selenium 
and 1% penicillin G (100 unit/ml)/streptomycin (100 μg/ml).  As described previously 
(Shu et al., 2001), cells were subcultured every 3-5 days by treatment with 0.05% trypsin 
and 0.53 mM EDTA at 37ºC.  SKPT cells were seeded on collagen-coated (5 μg/cm
2
) 12-
transwell filter inserts (12 mm diameter, 0.4 μm pore size) at 10
5 




), and the culture medium was changed every other day.  At 24 hr prior to 
experimentation, antibiotics were removed from the culture medium.  SKPT cells were 
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used 4 days after the initial seeding.  Transepithelial electrical resistance was measured 
prior to the experiments to ensure the integrity of cell monolayers.   
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Analyses 
RT-PCR was used to identify the expression of specific POT mRNA in SKPT 
cells.  In brief, total RNA was isolated from SKPT cells using an RNeasy Mini Kit 
(Qiagen, Valencia, CA).  The RNA was then reverse-transcribed in a 40 µl reaction 
mixture containing 200 U of Moloney murine leukemia virus reverse transcriptase and 
random primers.  cDNA was amplified with specific primers for all four oligopeptide 
transporters by PCR.  The primers were designed using the Vector NTI program 
(Invitrogen, Carlsbad, CA), and PCR was performed in a 60-μL reaction mixture 
containing 2 U of Taq DNA polymerase, 4 pmol each of the 5´ and 3´ primers for each 
POT, 0.2 μg of cDNA sample, 1.5 mM MgCl2, and 0.5 mM deoxytriphosphate nucleotide 
mixture.  Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a control 
for PCR analyses.  The positive controls for oligopeptide transporters were rat small 
intestine (PEPT1), rat kidney (PEPT2), and rat brain (PHT1 and PHT2).  The amplified 
products were separated on a 1.5 % agarose gel and visualized with ethidium bromide.  
Primers and PCR conditions for each POT are listed in the supplementary material (Table 
3.1).   
Carnosine Intracellular Accumulation and Transepithelial Transport Studies 
The uptake buffer consisted of 25 mM MES/Tris (pH 6.0) or 25 mM HEPES/Tris 
(pH 7.4), each containing 140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM MgSO4 
and 5 mM glucose.  For intracellular accumulation and transepithelial transport 
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experiments, the cell monolayers were washed and preincubated apically with 0.4 ml of 
pH 6.0 buffer and basolaterally with 1.2 ml of pH 7.4 buffer for 10 min at 37
o
C.  The 





C]mannitol; 10 μM each) was added to the apical or basolateral 
compartments, respectively, in the absence and presence of potential inhibitors.  Control 
buffer of 1.2 ml pH 7.4 or 0.4 ml pH 6.0 was added to the opposite compartment (i.e., no 
carnosine, mannitol or inhibitor).  Cells were then incubated for the indicated length of 
time at 37
o
C.  For transepithelial flux experiments, a 100-μl aliquot was collected from 
the opposite compartment from where drug was placed, and the radioactivity counted.  
For intracellular accumulation experiments, media were aspirated from both 
compartments and the monolayers were then washed 4 times from both sides with ice-
cold buffer.  The filters with monolayers were detached from the chamber, placed in a 
scintillation vial, and the cells were solubilized with 0.2 M NaOH and 1% SDS.  
Radioactivity was measured in solubilized cells (and buffer) with a dual-channel liquid 
scintillation counter (Beckman LS 6000 SC; Beckman Coulter Inc., Fullerton, CA).  
Protein concentrations were measured using the Bio-Rad DC protein assay (Bio-Rad 
Laboratories, Hercules, CA) with bovine serum albumin as the standard.  Mannitol was 
used to correct the uptake data of carnosine due to filter binding and extracellular content 
(Teuscher et al., 2000; Teuscher et al., 2004), as well as the transepithelial transport of 
carnosine due to paracellular flux (Shu et al., 2002).   
Efflux Studies 





C]mannitol (10 μM each) for 2 hr at 37
o
C.  Following incubation, monolayers 
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were washed four times from both sides with ice-cold buffer (no substrate present).  The 
monolayers were then incubated at 37
o
C with control buffer in both compartments (i.e., 
0.4 ml of pH 6.0 buffer in the apical side and 1.2 ml of pH 7.4 buffer in the basolateral 
side).  At specified times, 100-μl and 300-µl aliquots were taken from the apical and 
basolateral compartments, respectively, and replaced with fresh buffer.  Radioactivity 
was measured in the buffer samples with a dual-channel liquid scintillation counter, and 
efflux was expressed as a percentage relative to carnosine’s initial concentration in cells 
after the 2-hr loading period.   
Substrate Stability Studies 
Carnosine stability was evaluated in the apical, basolateral and intracellular 
compartments of SKPT cells.  Following apical or basolateral incubations of 
[
3
H]carnosine (10 µM) for 5, 10, 15, 60, 120, 180 and 300 min at 37
o
C, media were 
collected from the donor and receiver sides for analysis.  The monolayers were washed 
four times with ice-cold buffer, and the filters with monolayers were detached from the 
chamber.  The cells were mixed with 0.5 ml of Milli-Q water and then lysed by 
sonication for 30 sec x 5 times.  An equal volume of acetonitrile was added to the cell 
lysates, vortexed for 5 sec, and centrifuged at 14,000 g for 10 min at 4
o
C.  Cell 
supernatants were concentrated under cryovacuum (SpeedVac concentrator SVC 200H 
with Refrigerated Condensation Trap RT 4104, Savant Instrument Inc, Farmingdale, NY) 
and analyzed, along with buffer samples, by high-performance liquid chromatography 
(Model 515 Pump, Water, Milford, MA) with radiochromatography detection (Flo-One 
500TR, PerkinElmer Life and Analytical Sciences, Boston, MA).  Sample components 
were separated using a reversed-phase column (Supelco Discovery® C-18, 5 μm, 250 cm 
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× 4.6 mm, Supelco Park, Bellefonte, PA) subjected to a mobile phase of 0.1 M NaH2PO4 
and 0.075 % heptafluorobutyric acid, pumped isocratically at 1 ml /min.  Retention times 
for histidine and carnosine were 4.4 min and 7.9 min, respectively, under ambient 
conditions.  Carnosine stability was determined by its recovery and the appearance of 
histidine following the specified incubation periods.   
Kinetic Analyses 
The influx and efflux clearances of carnosine across SKPT cell membranes are 
depicted by the three-compartment model in Fig. 3.1A.  Variations in the amount of 
carnosine with time are described in each compartment according to the following mass 
















 )(    (3)   
  
where XA, XB and XC (pmol/mg protein) are the amounts of carnosine, respectively, in 
the apical, basolateral and cellular compartments; CA, CB and CC (pmol/µl) are the 
respective concentrations of carnosine in the apical, basolateral and cellular 
compartments; CLAC and CLBC (µl/min/mg protein) represent the influx clearances from 
the apical and basolateral compartments, respectively, to the cellular compartment; and 
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CLCA and CLCB represent the respective efflux clearances from the cellular compartment 
to the apical and basolateral compartments.  The transepithelial transport of carnosine is 










  A-to-B directional transport   (5) 
where CLAB and CLBA represent the transcellular clearances of carnosine from the apical 
to basolateral compartment and from the basolateral to apical compartment, respectively.  
Finally, the transcellular clearance can be described by: 
BeffluxACAB fCLCL .        (6)  
AeffluxBCBA fCLCL .        (7) 
where fefflux.A and fefflux.B represent the fraction of carnosine effluxed from the cellular 
compartment to the apical and basolateral compartments, respectively, at steady state.   
A Michaelis-Menten model was used to fit the concentration-dependent uptake 
data of carnosine, where V is the initial uptake rate, Vmax is the maximal rate of saturable 
uptake, Km is the Michaelis constant, and S is the substrate concentration (Eq. 8).  The 
unknown parameters (i.e., Vmax and Km) were determined by nonlinear regression 
analysis (GraphPad Prism v4.0; GraphPad Software, Inc. San Diego, CA) and a 
weighting factor of unity.  The quality of fit was determined by evaluating the coefficient 
of determination (r
2










        (8) 
While other transport models were attempted (i.e., saturable component plus linear term; 
two saturable components), they did not fit the data as well as a saturable component 
alone.   
Statistical Analyses 
All data were reported as mean ± SE.  Cellular uptakes of carnosine were 
standardized for the total amount of protein (mg) in SKPT cells.  Statistical differences 
were determined between groups by analysis of variance followed by Dunnett’s test for 
pairwise comparisons with the control group (GraphPad Prism, v4.0; GraphPad Software, 




RT-PCR Analyses of POT Expression in SKPT Cells 
Specific POT transcripts were sought in SKPT cells and kidney lysates (Fig. 3.2), 
while intestinal lysates served as a positive control for PEPT1 mRNA and brain lysates 
served as a positive control for PHT1 or PHT2 mRNA.  Although kidney lysates 
expressed all four members of the POT family, only PEPT2 and PHT1 transcripts were 
expressed in SKPT cells.  GAPDH, which served as a housekeeper gene, was strongly 
expressed in all samples.  Given the predominant role of PEPT2 in renal reabsorption 
(Takahashi et al., 1998; Inui et al., 2000; Ocheltree et al., 2005; Shen et al., 2007), the 
presence of PEPT2 mRNA in SKPT cells suggests that this cell line was a good model to 
study the proximal tubular transport of peptides (e.g., carnosine) in kidney.  The presence 
of PHT1 mRNA in SKPT cells also allows us to evaluate whether this peptide-histidine 
transporter has a functional role in the disposition of small peptides in kidney.   
Time Course of Carnosine Intracellular Accumulation and Transepithelial 
Transport 
As observed Fig. 3.3A, the apical uptake of carnosine was substantially greater 
than its uptake from the basolateral surface of SKPT cell monolayers ( 15-fold).  It was 
also observed that carnosine uptake was linear for 60 min at the apical surface and for 30 
min at the basolateral surface.  As a result, initial rates were determined at 15 min for 
both apical and basolateral uptakes in subsequent experiments.  At 180-300 min, the 
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apical uptake of carnosine reached a plateau value of approximately 220 pmol/mg 
protein.  Using the experimentally determined value for intracellular volume of SKPT 
cells (i.e., 2.0±0.1 µl/mg of protein, see appendix A), and given that the extracellular 
medium concentration of carnosine was 10 µM, the intracellular to extracellular 
concentration ratio of carnosine was 11, indicating the presence of active uptake 
process(es) at the apical membrane (possibly  PEPT2 and/or PHT1).  However, when 
carnosine was introduced from the basolateral compartment, the uptake reached a plateau 
value of only 15 pmol/mg protein.  This result translated into an intracellular to 
extracellular concentration ratio of only 0.8, indicating the absence of a concentrative 
mechanism for carnosine uptake at the basolateral membrane.   
In contrast to its intracellular accumulation, the apical-to-basolateral transcellular 
flux of carnosine was smaller than its basolateral-to-apical transcellular flux ( 2-fold) 
(Fig. 3.3B).  This finding suggests that although carnosine preferentially accumulates in 
the cell from the apical surface, its basolateral efflux is very limited thereby driving 
carnosine back to the apical compartment.  This aspect is further examined in the efflux 
studies below. 
Efflux of Carnosine  
In order to test our interpretation of the transcellular transport data and to better 
understand the fate of carnosine once inside the cell, the efflux of carnosine was 
evaluated after 2 hr of apical preloading.  As shown in Fig. 3.3C, about 40% of carnosine 
was effluxed from the cell to the apical compartment at 60 min and about 4% of cellular 
carnosine was effluxed to the basolateral compartment.  When a single exponential term 
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was used to fit the efflux-time profile [i.e., Y = Yss  ( 1 - e –Keff  t )], we found that 66% 
of carnosine was effluxed from the cellular to apical compartment while only 4.7% of 
carnosine was effluxed to the basolateral compartment at steady state (i.e., fefflux.A = 0.66 
and fefflux.B = 0.047, respectively).  This finding is in accordance with the transepithelial 
transport data, which suggested a very minimal efflux of carnosine across the basolateral 
membrane. 
Kinetics Analysis of Carnosine Cellular Transport 
Based on the slopes of the transport versus time profiles depicted in Fig. 3.3B, the 
A-to-B transepithelial rate of carnosine was 1.99 pmol/min/mg protein while the B-to-A 
transepithelial rate of carnosine was 3.74 pmol/min/mg protein.  Given that these studies 
were performed with 10 µM concentrations in the donor compartment, and according to 
Eqs. 4 and 5, the transepithelial clearances were calculated as: CLAB = 0.20 µl/min/mg 
and CLBA = 0.37 µl/min/mg.  With a knowledge of the fractional effluxes of carnosine to 
both apical and basolateral compartments (see efflux studies above), and the 
transepithelial clearances determined here, the influx clearances of carnosine were 
determined according to Eqs. 6 and 7, in which: CLAC = 4.25 µl/min/mg and CLBC = 0.57 
µl/min/mg.  Finally, the efflux clearances of carnosine were calculated according to Eqs. 
1 and 2 (now that all other parameters are known), such that: CLCA = 0.69 µl/min/mg and 
CLCB = 0.018 µl/min/mg.  All clearance values are summarized in the cellular models 
shown in Fig. 3.1.   
Proton-Dependent Uptake of Carnosine 
 
 74 
To determine whether the uptake of carnosine was stimulated by an inwardly-
directed proton gradient, we evaluated the uptake of carnosine from both membrane 
surfaces at various pH values.  This was achieved by varying pH of the donor side from 
5.5 to 7.4 while keeping the apical side at pH 6.0 for basolateral uptakes and the 
basolateral side at pH 7.4 for apical uptakes.  As shown on Fig. 3.4A, the apical uptake of 
carnosine demonstrated a marked dependency on extracellular pH values and was 
maximal at pH 6.5, which is consistent with the proton-substrate symport characteristics 
of the PEPT2 and PHT1.  In contrast, the basolateral uptake of carnosine (Fig 3.4B) was 
more insensitive to changes in external pH (maximal at pH 6.5; p>0.05 for all 
comparisons).  Carnosine is a basic dipeptide with pKa values of 2.76, 6.78 and 9.36 
(Nielsen et al., 2002).  Therefore, as the pH of the environment increases from 5.5 to 7.4, 
carnosine becomes less basic (Fig. 3.4C).  Thus, at pH 5.5 carnosine is 95% ionized 
(NH3
+
), at pH 6.5 carnosine is 65% ionized (NH3
+
), and at pH 7.4 carnosine is 15-20% 
ionized (NH3
+
).  While higher pH values would favor an increased passive uptake of 
carnosine, the PEPT2-mediated of dipeptide is not favored due to a reduction in proton 
motive force.  Moreover, pH may also affect the protonation state of the peptide 
transporter protein.  The multiple influences of pH, along with membrane potential, 
should be considered when drawing conclusions about peptide transporter activity.   
Effect of Potential Inhibitors 
Specificity of carnosine transport at the apical and basolateral membranes of 
SKPT cells was evaluated by co-incubating the substrate with potential inhibitors.  In 
particular, the PEPT2-mediated uptake of carnosine was probed by performing studies in 
the absence and presence of GlySar, while the PHT1-mediated uptake of carnosine was 
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probed with histidine.  As shown in Fig. 3.5A, the apical uptake of carnosine was 
unaffected by 1, 2 and 5 mM of histidine (a potent inhibitor of PHT1).  In contrast, 1 and 
2 mM of GlySar (a classic inhibitor of PEPT2) reduced the apical uptake of carnosine by 
90%.  Self-inhibition experiments revealed that 1 and 2 mM of unlabeled substrate 
inhibited the apical uptake of radiolabeled carnosine by 96%.  At the basolateral 
membrane, carnosine uptake was unaffected by 1 mM of histidine but reduced by 90-
99% in the presence of 1 mM of GlySar, unlabeled carnosine (self-inhibition), or 
cefadroxil (Fig. 3.5B).   
Concentration-Dependent Uptake of Carnosine   
The concentration dependency of carnosine was characterized at both the apical 
and basolateral surfaces of SKPT cells.  At the apical membrane, carnosine uptake was 
saturable (Fig. 3.6A) with Michaelis-Menten parameters of Vmax=659±27 
pmol/mg/15min and Km=49±8 µM.  Carnosine was also found to have saturable transport 
kinetics at the basolateral membrane (Fig. 3.6B) where the Vmax=27.4±1.3 
pmol/mg/15min and Km=108±10 µM.  Linear transformations of the data, as shown in 
Woolf-Augustinsson-Hofstee plot inserts, suggest the involvement of a single specific 
transporter for the uptake of carnosine at each membrane.  However, compared to the 
apical transporter (i.e., PEPT2), the basolateral transporter has a 24-fold lower capacity 
and a 2-fold lower affinity.  The results are consistent with the previous cellular 
accumulation, transepithelial transport and pH-dependent findings, in which different 
transport systems appear to be involved for carnosine at the apical and basolateral 
membranes of SKPT cells.   
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Stability of Carnosine  
As shown in Fig. 3.7, carnosine remained intact in the donor compartment, 
whether introduced from the apical or basolateral side, for up to 300 min of incubation.  
However, there was some degradation of carnosine in the intracellular compartment after 
the first hour of incubation.  In this regard, carnosine was > 94% intact for the first 15 
min of incubation while being about 87% intact at 60 min and 81% intact at 300 min of 
incubation.  Overall, these findings indicate that carnosine was mostly intact during the 
intracellular accumulation, transepithelial transport and efflux experiments, and 
completely stable for those experiments in which incubation times were only 15 min (i.e., 




Carnosine, a naturally-occurring dipeptide and dietary supplement, has been 
shown to have some renoprotective qualities (Fujii et al., 2003; Fujii et al., 2005; Janssen 
et al., 2005; Kurata et al., 2006) yet no studies have delineated its mechanism of transport 
in kidney.  In the present study, several new findings were revealed with respect to the 
transport mechanisms of carnosine in SKPT cells.  Specifically, we have demonstrated 
that:  1) PEPT2 is the only peptide transporter responsible for the apical uptake of 
carnosine; the basolateral transporter is saturable, inhibited by dipeptide/mimetic 
substrates but non-concentrative, thereby, suggesting a facilitative carrier, 2) PHT1 
mRNA is expressed in rat kidney lysates and SKPT monolayers, however, this 
peptide/histidine transporter is functionally inactive at both the apical and basolateral 
membranes of the cell, and 3) the apical-to-basolateral transepithelial transport of 
carnosine is severely rate-limited by its cellular efflux across the basolateral membrane 
(i.e., CLCB/CLAC ratio=0.004).  In contrast, the basolateral-to-apical transepithelial 
transport of carnosine is rate-limited to a minor extent by its cellular influx at the 
basolateral membrane (i.e., CLBC/CLCA ratio=0.8).  Thus, the directionality of 
transcellular kinetics can more fully be appreciated by understanding all of the influx and 
efflux parameters for a given substrate in the cellular compartment model (Fig. 3.1).   
Our findings regarding the influx and efflux clearances of carnosine in SKPT cells 
are in agreement with studies using GlySar as a model substrate in this cell line.  In 
particular, Bravo et al. (Bravo et al., 2005) reported similar apical-to-basolateral and 
basolateral-to-apical fluxes of GlySar even though the apical uptake of dipeptide was 
 
 78 
about 5x greater than its basolateral uptake in SKPT cells.  In the study by Neumann et 
al. (Neumann et al., 2004) the transepithelial apical-to-basolateral flux of GlySar was 
only 28% higher than its reverse flux (i.e., basolateral to apical direction) in SKPT cells 
despite the apical uptake of GlySar being about 3.5x greater than its basolateral uptake.  
The values in our study were 2-fold and 12-fold, respectively, for the preferential 
basolateral-to-apical flux (Fig. 3.3B) and apical intracellular accumulation (Fig. 3.3A) of 
carnosine.  To account for the anomaly between transcellular transport and apical uptake, 
Bravo et al. (Bravo et al., 2005) speculated that a low basolateral transport activity may 
limit the carrier-mediated transepithelial flux of GlySar in SKPT cells.  Our kinetic 
analysis agrees with this assessment and has demonstrated that carnosine is effluxed at a 
much slower rate across the basolateral versus apical membrane of SKPT cells (Fig. 
3.3C).   
 The efflux studies suggest that once carnosine enters the epithelial cells of kidney 
proximal tubule from the luminal side, the dipeptide accumulates substantially within the 
cell rather than being transported to the blood side.  Carnosine may then recycle back to 
the luminal compartment.  Our results show that carnosine has an 11-times greater 
concentration in SKPT cells as compared to medium and that its cell-to-apical efflux is 
about 10 times greater than the substrate’s cell-to-basolateral efflux.  We reported a 
similar finding for carnosine in rat choroid plexus primary cell cultures (Teuscher et al., 
2004), where its intracellular to extracellular concentration ratio was approximately 135 
to 1 and apical efflux was about 4 times greater than basolateral efflux.   
The SKPT cell line, derived from rat kidney proximal tubule cells, has been used 
previously as a model system to study the mechanism of peptide/mimetic transport in 
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epithelial cells of kidney proximal tubule.  In this regard, functional, Northern blot and 
immunoblot analyses have demonstrated conclusively that SKPT cells express the high-
affinity, low-capacity (i.e., “renal”) peptide transporter PEPT2 but not PEPT1 (Brandsch 
et al., 1995; Ganapathy et al., 1995; Shu et al., 2001).  Moreover, confocal laser scanning 
microscopy showed immunostaining of PEPT2 in the apical but not basolateral 
membrane (Bravo et al., 2004).  The current study has corroborated these findings, but 
has also shown the functional activity of a renal basolateral peptide transporter in SKPT 
cells (Figs. 3.4B, 3.5B and 3.6B) and the presence of the peptide/histidine transporter 
PHT1 in this cell line as well as rat kidney lysates (Fig. 3.2).  While several studies have 
reported on the accumulation of GlySar in SKPT cells (Brandsch et al., 1995; Ganapathy 
et al., 1995; Brandsch et al., 1997; Ganapathy et al., 1997; Ganapathy et al., 1998; 
Sugawara et al., 2000), only apical uptake was investigated and a non-physiologic, 
synthetic dipeptide was used as a model substrate.  Moreover, the potential roles of the 
renal basolateral peptide transporter and PHT1 were not appreciated at that time and, as a 
result, studies were not appropriated designed to probe whether or not other peptide 
transporters might be involved in renal trafficking of peptides at the plasma membrane.  
The high-affinity uptake of carnosine at the apical membrane of SKPT cells (i.e., 
Km=49 µM) is comparable to the PEPT2-mediated uptake of carnosine in rat choroid 
plexus primary cell cultures (Km=34 μM) (Teuscher et al., 2004) and whole tissue 
(Km=39 μM) (Teuscher et al., 2001), and rat neonatal astrocytes (Km=43 μM) (Xiang et 
al., 2006).  This finding, along with the proton-dependence, concentration-dependence 
and inhibitor specificity of carnosine in SKPT monolayers, supports the contention that 
PEPT2 is responsible for its uptake at the apical surface of these cells.  On the other hand, 
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the saturable but non-concentrative uptake of carnosine at the basolateral membrane, 
along with its preferred uptake over efflux at this membrane (i.e., CLBC/CLCB ratio=32), 
would suggest that the basolateral transporter of carnosine is facilitative in the inward 
direction.  Based on functional experiments in MDCK cells, Inui and coworkers (Terada 
et al., 2000; Sawada et al., 2001; Terada and Inui, 2004) reported that the renal 
basolateral peptide transporter was distinct from that of known peptide transporters (i.e., 
PEPT1 and PEPT2) and the intestinal basolateral peptide transporter.  They also 
suggested that the basolateral peptide transporter was facilitative and that it was involved 
in the cellular uptake, but not cellular efflux, of small peptides in the MDCK cell line.  
MDCK cells, however, display features of distal tubules or collecting ducts (Handler, 
1986) as opposed to proximal tubules where peptide reabsorption occurs (Shen et al., 
1999).  Moreover, although MDCK cells express a proton-peptide cotransporter at the 
apical membrane, its kinetic characteristics are that of PEPT1 and not PEPT2 (Brandsch 
et al., 1995).  As a result, the SKPT cell line appears to have greater relevance to peptide 
transport in kidney.  Notwithstanding these differences in experimental model, the 
precise nature of the renal basolateral transporter is uncertain as long as the clone of this 
protein remains unavailable.   
In conclusion, despite the substantial cellular uptake of carnosine by PEPT2 at the 
apical membrane, this dipeptide is expected to have minimal tubular reabsorption into 
blood due to its very limited efflux across the basolateral membrane.  This is important 
because, once inside the cell, carnosine may accumulate (as intact dipeptide or 
constituent amino acids) and have beneficial renoprotective properties.  Although cellular 
uptake of carnosine at the renal basolateral transporter is fairly low when compared to 
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luminal uptake, secretion across the cell may be possible, although minor, because of its 
favorable efflux kinetics at the apical membrane.  These findings elucidate, for the first 
time, a complete picture of the cellular kinetics of carnosine in SKPT cells and, more 
importantly, the influence of influx and efflux clearances on transepithelial transport.  
Future studies will be performed with carnosine in wild-type and PEPT2 null mice to 
further probe the in vivo pharmacokinetics and pharmacodynamics of this naturally-
occurring dipeptide and dietary nutrient supplement.   Moreover, a greater effort should 




ABBREVIATIONS:  GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GlySar, 
glycylsarcosine; PEPT, peptide transporter; PHT, peptide/histidine transporter; POTs, 
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Figure 3.1  Schematic representation of the SKPT cellular model in which CLAC and 
CLBC represent the influx clearances from the apical and basolateral compartments, 
respectively, while CLCA and CLCB represent the respective efflux clearances to the apical 
and basolateral compartments (A);  CLAB represents the apical-to-basolateral 
transepithelial clearance and CLBA represents the basolateral-to-apical transepithelial 
clearance (B).  The clearance values are those determined experimentally for carnosine in 
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Figure 3.2  RT-PCR analysis of peptide transporter mRNA in SKPT cells, and in kidney, 
intestine and brain lysates (4 µg total RNA).  Samples were separated on a 1.5% agarose 
gel, visualized with ethidium bromide, and screened for PEPT1 and PEPT2 transcripts (A) 
and for PHT1 and PHT2 transcripts (B).  GAPDH controls for rat brain, intestine, kidney 
and SKPT cDNA samples are also displayed (C).  In each gel, the right-hand lane is a 100 






























































































Figure 3.3  Intracellular accumulation (A) and transcellular transport (B) of 10 µM 
[
3
H]carnosine as a function of time in SKPT cell monolayers at 37°C.  The cellular efflux 
(C) of [
3
H]carnosine was determined after preloading the cells from the apical side with 
10 μM carnosine for 2 hr at 37°C.  For all experiments, the buffer pH was 6.0 in the 
apical compartment and 7.4 in the basolateral compartment.  Data are expressed as mean 
± SE (n=3-5). 
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Figure 3.4  Effect of pH on the 15-min uptake of 10 µM [
3
H] carnosine in SKPT cell 
monolayers at 37°C from the apical (A) compartment (basolateral pH maintained at 7.4) 
and from the basolateral (B) compartment (apical pH maintained at 6.0).  Data are 
expressed as mean ± SE (n=3-6).  ** p < 0.01, as compared to pH 7.4.  Relationship 





















































































































































































Figure 3.5  Effect of potential inhibitors on the 15-min apical (A) and basolateral (B) 
uptake of carnosine in SKPT cell monolayers at 37°C.  For all experiments, the buffer pH 
was 6.0 in the apical compartment and 7.4 in the basolateral compartment.  Data are 



























































































Figure 3.6  Effect of concentration on the 15-min uptake of 1-500 µM [
3
H]carnosine 
from the apical (A) and basolateral (B) sides of SKPT cell monolayers at 37°C.  For all 
experiments, the buffer pH was 6.0 in the apical compartment and 7.4 in the basolateral 
compartment.  Data are presented as mean ± SE (n=3-6); the inset is a Woolf-
Augustinsson-Hofstee plot of the transformed data (V, pmol/mg/15min versus V/S, 





































Figure 3.7  Stability of carnosine in the apical, basolateral, and intracellular 
compartments of SKPT cell monolayers as a function of time (pH 6.0 buffer in apical 
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Chapter 4  
 
SIGNIFICANCE OF PEPT1 IN THE IN SITU INTESTINAL 
PERMEABILITY OF GLYCYLSARCOSINE IN WILD-
TYPE AND PEPT1 KNOCKOUT MICE 
ABSTRACT 
Purpose.  To define the in situ intestinal transport properties of glycylsarcosine (GlySar) 
in PEPT1
+/+
 (wild-type) and PEPT1
-/-
 (knockout) mice, and to delineate the relative 
importance of PEPT1 in the intestinal absorption of small peptides. 
Methods.  An in situ single-pass intestinal perfusion model was used to assess the 
effective permeability of GlySar in both wild-type and PEPT1 knockout mice.  In 
particular, [
3
H]GlySar (10 µM) was perfused in 8 cm of proximal small intestine at a rate 
of 0.1 ml/min for 90 minute as a function of pH, potential inhibitors and substrate 
concentration.  Permeability was calculated as: Peff = -Qln(Cout/Cin)/(2πRL), after 
correcting for water flux with [
14
C]PEG 4000 (a nonabsorbable marker).   
Results.  Permeability of [
3
H]GlySar was dramatically reduced in PEPT1 knockout mice 
as compared to wild-type mice (>20-fold reduction; p<0.001).  Further, the permeability 
of [
3




change in the integrity of small intestinal epithelia in mice.  GlySar uptake was found to 
be pH-stimulated in wild-type animals with a maximum permeability being observed at 
pH 5.5;  no such pH effect was found in the PEPT1 knockout mice.  Transport specificity 
was confirmed by evaluating the permeability of GlySar in the presence of potential 
inhibitors.  In wild-type mice, GlySar permeability was significantly reduced by the 
dipeptides carnosine, GlySar and GlyPro, the ACE inhibitor captopril, the 
aminocephalosporin cefadroxil, and the antiviral prodrug valacyclovir (p<0.01).  In 
contrast, the amino acids Gly and L-His, the active parent moiety acyclovir, and cefazolin 
(a cephalosporin lacking an α-amino group) had no effect.  Saturable kinetics was 
observed for GlySar in wild-type mice with a Km value of about 10 mM. 
Conclusions.  PEPT1 is responsible for at least 90% of dipeptide uptake in the small 
intestine and exhibits low-affinity kinetics for GlySar, a finding that is consistent with 
previous in vitro studies.  These results suggest that PEPT1 will play a crucial role in the 






Protein is an important part of our daily diet.  A typical western diet usually 
contains 70-100 g protein per day.  In addition to dietary protein, saliva and 
gastrointestinal tract secretions also contribute a significant amount of protein (~35g/day) 
(Ganapathy et al., 2006).  In gastrointestinal lumen, the proteins are converted into large 
peptides by gastric and pancreatic proteases, which subsequently undergo further 
hydrolysis by various peptidases in the brush border membrane of intestinal epithelium 
into small peptides (80%) and free amino acids (20%) (Ganapathy et al., 2006).  The final 
end products of protein digestion are absorbed into the enterocytes predominately in the 
form of di- and tripeptides as opposed to free amino acids (Matthews, 1975).  Once inside 
the enterocytes, the majority of the di- and tripeptides undergo further hydrolysis into 
their constituent amino acids by cytoplasmic peptidases and exit the epithelial cells via 
different basolateral amino acid transporters.  A small amount of small peptides that are 
resistant to cytoplasmic peptidases exit the enterocytes intact across the basolateral 
membrane through a basolateral peptide transporter that has yet to be cloned (Terada et 
al., 1999).  Furthermore, there are regional differences in small intestinal epithelium in 
respect to their absorptive capacities for free amino acids and small peptides.  While the 
proximal small intestine has a greater absorption capacity for small peptides compared to 
the distal small intestine, the distal intestine has a greater absorptive capacity for amino 
acids compared to the proximal small intestine (Matthews et al., 1971).  In addition, the 
activities of brush border membrane peptidase are much higher in the ileum than in the 




acids as the luminal contents move along the intestine while the concentration of small 
peptides decrease.  
Proton-coupled oligopeptide transporters (POTs) are membrane proteins that are 
responsible for translocating small peptides and peptidomimetics across a biological 
membrane via an inwardly-directed proton gradient and negative membrane potential.  
Thus far, four members of the POT superfamily, specifically PEPT1 (SLC15A1), PEPT2 
(SLC15A2), PHT1 (SLCA4) and PHT2 (SLCA3), have been identified in mammals 
(Herrera-Ruiz and Knipp, 2003; Daniel and Kottra, 2004).  PEPT1, being expressed on 
the apical membrane of enterocytes in small intestine (Ogihara et al., 1996; Walker et al., 
1998; Groneberg et al., 2001), is believed to be the primary POT responsible for small 
intestinal absorption of di/tripeptides and peptide-like therapeutic agents.  PEPT1 is 
characterized as a high-capacity, low-affinity transporter.  It was first isolated and cloned 
from a rabbit  intestine cDNA library (Fei et al., 1994), which subsequently lead to the 
cloning of PEPT1 from human (Liang et al., 1995), rat (Saito et al., 1995; Miyamoto et 
al., 1996) and mouse (Fei et al., 2000) intestinal cDNA libraries.  It has been found that 
PEPT1 is highly homologous (~ 80%) across species (Liang et al., 1995; Miyamoto et al., 
1996; Fei et al., 2000).  PEPT1 is predicted to contain 12 transmembrane domains with 
both C and N terminals facing the cytosolic side, and protein sizes from 707 to 710 in 
amino acids depending on the species.  The genomic organization of human PEPT1 
shows high similarity with its mouse orthologue (Urtti et al., 2001).  In addition, studies 
suggest that mouse and human have comparable intestinal expression patterns and levels, 
whereas PEPT1 expression level in the rat is several fold higher (Kim et al., 2007).  




peptidomimetic therapeutic agents of different conformation, size, polarity and charge 
(e.g., β-lactam antibiotics, ACE inhibitors, renin inhibitors, bestatin and antiviral prodrug 
valacyclovir), and acts as a vehicle for their effective intestinal absorption.  Due to its 
broad substrate specificity and high capacity, PEPT1 is considered to be a very attractive 
target for drug delivery to improve the bioavailibility of low permeable drugs.   
Because of PEPT1’s putative physiological and pharmacological importance in 
the absorption of di/tripeptides and peptidomimetic in the small intestine, PEPT1 is the 
most extensively studied transporter among the POT members.  However, most of the 
previous studies were obtained from in vitro models such as cell transfection with 
PEPT1, Caco-2 cells, brush border membrane vesicles (BBMV) and Ussing chambers 
using non-physiological conditions that lack an intact blood supply.  Moreover, both 
human and rat small intestine, in addition to expressing PEPT1,  have been shown to 
express PHT1 and PHT2 transcripts (Herrera-Ruiz et al., 2001), where PHT1 is expressed 
in the villous epithelium of small intestine (Bhardwaj et al., 2006).  Due to the existence 
of multiple peptide transport systems with overlapping substrate specificity in the small 
intestine, the previous in situ intestinal perfusion studies in rat do not isolate the 
individual role of a single gene product, PEPT1, in relation to other peptide transporters 
(or other processes).  Thereby, by utilizing PEPT1 deficient mice, we can assess the 
relative role of PEPT1 under physiological conditions for the absorption of small peptides 
and peptidomimetics.  Therefore, the aim of the present study is to delineate the relative 
importance of PEPT1 in the intestinal absorption of small peptides by defining the in situ 










MATERIALS AND METHODS 
Animals 
Animals studies were carried out in accordance with the Guide for the Care and 
Use of Laboratory Animal as adopted and promulgated by the U.S National Institutes of 
Health.  Gender matched 8-10 weeks old PEPT1
+/+
 (wild-type) and PEPT1
-/-
 (null) mice 
were used for all experiments.  The mice were kept in temperature controlled 
environment with a 12-h light and 12-dark cycle, and received a standard diet and water 





H]GlySar (0.5 Ci/mmol), [
3
H]metoprolol (64.6 Ci/mmol) and [
14
C]inulin (2 
mCi/g) were purchased from Moravek Biochemicals and Radiochemicals (Brea, CA).   
[
14
C]PEG 4000 (1.5 mCi/g) and [
3
H]mannitol (20 Ci/mmol) were purchased from 
American Radiolabeled Compounds (St. Louis, MO).  Unlabelled PEG 4000 was 
obtained from Mallinckrodt Baker, Inc (Phillipsburg, NJ).  Acyclovir and valacyclovir 
were generous gifts from GlaxoSmithKline (Research Triangle Park, NC).  All other 
chemicals were acquired from Sigma –Aldrich (St. Louis, MO).   




Gender-matched mice of the genotype PEPT1
+/+
 (wild-type) and PEPT1
-/-
 (null) 
were fasted over night with free access to water prior to each experiment.  Following 
anesthesia with sodium pentobarbital (40-60 mg/kg, I.P), surgery was performed on the 
animals on top of a heating pad to maintain the body temperature.  Isopropyl alcohol was 
used to sterilize the abdominal area and a 1.5 cm of midline longitudinal incision was 
made to expose the small intestine.  An 8 cm segment of the proximal jejunum (i.e., ~2 
cm distal to the ligament of Treitz) was isolated followed by incisions at both the 
proximal and distal ends (8 cm separation) and the lumen was gently rinsed with warm 
isotonic saline solution.  Glass cannulas (2.0 mm outer diameter) that were attached to 
rubber tubings were inserted at both ends of the jejunal segment and secured in place 
with silk sutures.  Following the cannulation, the isolated intestinal segment was covered 
with saline-wetted gauze and parafilm to prevent dehydration.  After the surgical 
procedure, the animals were transferred to a temperature-controlled Plexiglas perfusion 
chamber (31
o
C) to maintain the body temperature during the perfusion experiment.  The 
inlet tubing was connected to a 10 ml syringe placed on a perfusion pump (Harvard 
Apparatus, Model 22, South Natick, MA) and the outlet tubing was placed in a collection 
vial.  The perfusion solution contained 10 mM MES, 135 mM NaCl, 5 mM KCl and 
0.01% (w/v) PEG 4000 at pH 6.5.  [
3
H]GlySar (10 µM) was perfused through the 
proximal jejunal segment at a rate of 0.1 ml/min for 90 minutes as a function of pH, 
potential inhibitors, and substrate concentration.  The exiting perfusate was collected at 
every 10 minutes for 90 minutes.  A 100 µL aliquot of each collected sample was added a 
vial containing 5.5 ml of scintillation cocktail (Ecolite, MP Biomedicals, Solon, OH), and 




6000 SC; Beckman Coulter Inc., Fullerton, CA).  Following the experiment, the animal 
were euthanized by pentobarbital overdose solution and disposed of according to the 
rules and regulations of Radiation Safety Service and ULAM. We used [
3
H]GlySar, a 
hydrolysis-resistant dipeptide, as our model compound.  [
14
C]PEG 4000 was added to the 
perfusion buffer as a non-absorbable marker to measure water flux.  
Data Analysis 
The effective permeability (Peff) was determined from the steady-state loss of drug 
from the perfusate as it flows through the intestine according to a complete radial mixing 
(parallel tube) model (Ho and Higuchi, 1974; Amidon et al., 1980) : 
 
where Q is the perfusion rate (0.1 ml/min), R is the radius of the intestinal segment (0.1 
cm) and L is the length of the perfused intestinal segment (8 cm).  The Cin and Cout 
represent the inlet and outlet concentrations of drug.  Cout was corrected for the water 
transport (flux) that occurs during the perfusion according to changes in concentration of 
non-absorbable compound PEG 4000: 
 
where Cperfusate is the actual concentration of drug in the exiting perfusate, and PEGin and 
PEGout are the inlet and outlet concentrations of PEG 4000.  Steady-state was assessed 
when the inlet over outlet concentrations of PEG 4000 approach a constant value, which 




Initially, PEG 4000 was used as the non-absorbable marker to correct for the 
water absorption/secretion during the mouse intestinal perfusion (Loria et al., 1976).  
However, based on a comparison study of different water flux measurements, PEG 4000 
(compared to gravimetric method and inulin) appears to overestimate the water secretion 
by approximately 21% for mouse intestinal perfusion (Appendix B).  Therefore, all of the 
water flux corrections assessed by PEG 4000 were adjusted by an average water flux 
correction of 14%, as determined by the 3 methods (i.e., non-absorbable markers PEG 
4000 plus inulin plus gravimetric method). 
Estimation of Intrinsic Membrane Parameters 
The effective permeability determined by Eq. 1 includes a combination of the 
unstirred aqueous layer permeability (Paq) and the intrinsic membrane permeability (Pw).   
 
Therefore, it is critical to isolate the intrinsic membrane permeability in order to 
determine intrinsic membrane uptake parameters such as Km and Jmax due to a 
transporter(s) (e.g., PETP1).  The aqueous and intrinsic (unbiased) membrane 
permeabilities were estimated using a modified boundary layer model (Johnson and 





where D is the aqueous diffusion coefficient. Graetz number (Gz) (the ratio of the mean 
tube residence time to the time required for radial diffusional equilibration ) and unitless 
constant A were estimated from the following expressions: 
 
A = 10.0Gz +1.01  where       0.004  ≤ Gz <0.01 
A = 4.5Gz + 1.065  where   0.01  ≤ Gz < 0.03 
A = 2.5Gz + 1.125  where  0.03 ≤ Gz 
Drug concentrations at the membrane surface (Cw) and the intrinsic membrane 
permeability (Pw) were calculated as follows: 
   
 
Regression of intrinsic membrane permeability (Pw) vs. membrane surface 
concentration of drug (Cw) can be used to determine the unbiased intrinsic membrane 
parameters:  
 
where Jmax, is the maximum flux, Km is the intrinsic Michaelis constant, and Pm is the 




The intrinsic membrane uptake parameters Jmax and Km can also be expressed as a 
function of flux J and membrane surface concentration.   
 
  
The flux at steady-state is the product of the effective drug permeability, Peff, and 
the bulk drug concentration, Cin.  
The apparent biased kinetic parameters,   and 
 
where the aqueous resistance 
is not subtracted from the total resistance, can be estimated as a function of effective 
permeability and inlet concentration. 
 
 
When the aqueous layer is ignored, the membrane parameters obtained are biased, 
and Km is overestimated.  Therefore, it is necessary to either eliminate or account for the 
effect of this aqueous layer resistance in order to obtain the true membrane parameters.   
Estimation of Aqueous Diffusion Coefficient 
The diffusion coefficient (D) of GlySar used in estimation of aqueous 
permeability (Eq. 4) was determined according to the Hayduck-Laudie’s expression 





Where η is the viscosity of water (0.6915 cP at 37
o
C), VA is the solute molar 
volume at normal boiling point (cm
3
/g/mol), and D is the binary diffusion coefficient at 
infinite dilution (cm
2
/s).  Molar volume (VA) for GlySar was estimated using Schroeder’s 
additive method.  The values for VA and D for GlySar are 140 cm
3
/g/mol and 0.00066 
cm
2
/min, respectively.   
Gz = 0.08285 
A= 1.3321 




Data were reported as mean ± S.E.  A two-tailed student t-test was used to 
compare statistical differences between two groups.  For multiple comparisons, one-way 
analysis of variance (ANOVA) was used followed by Dunnett’s test for pairwise 
comparisons with the control group (GraphPad Prism, v4.0; GraphPad Software, Inc., La 











As observed in Fig. 4.1, permeability of 10 µM GlySar in PEPT1
-/-
 mice was 
about 20x lower than that of wild-type mice demonstrating the crucial role of PEPT1 
transporter in absorption of GlySar.   
Control for Passive and Paracellular Permeability 
To assess whether the deletion of PEPT1 had any influence on membrane 





 mice to investigate if any differences in paracellular and passive permeability 
occurred respectively, between the two genotypes.  As depicted in Fig 4.2  and Fig 4.3, 
no significant differences were observed in permeability of mannitol or metoproplol 





 mice are due to PEPT1-mediated transport rather than a change in 
integrity of brush border membrane in the small intestine. 
pH-Dependent Studies 
Permeability of 10 µM GlySar was evaluated at various pH values in order to test 
for a proton-dependent uptake of GlySar by PEPT1.  As demonstrated in Fig. 4.3, there 
was a minor effect of pH on GlySar permeability in wild-type mice, the optimal uptake 
being at pH 5.5 (Fig 4.4A), and no effect of pH  on PEPT1 deficient mice (Fig 4.4C), 




effect on GlySar permeability in-situ was not as prominent as in vitro models because the 
microclimate pH is relatively insensitive to pH changes in the bulk phase (Lucas et al., 





 exchanger inhibitor (Arakawa and Hara, 1999; Mirossay et al., 1999), decreases 
GlySar permeability in a dose dependent manner (Fig 4.4B).  In the presence of 0.1 mM 
DMA, the GlySar permeability was not altered, whereas the presence of 1 and 2 mM 
DMA significantly reduced the GlySar permeability (p<0.05).     
Concentration-Dependent Studies 
To determine the PEPT1-mediated uptake parameters of GlySar (i.e., Jmax and 
Km), dipeptide permeability was evaluated over a wide concentration range (0.01-200 
mM total substrate in perfusate) in wild-type mice.  As observed in Fig. 4.5, GlySar 
exhibited Michaelis-Menten uptake kinetics where the estimated apparent kinetic 
parameters were J´max = 4.4 nmol/cm
2
/sec and K´m = 19.8 mM (Fig 4.5A).  When 
intestinal wall concentrations of GlySar (Cw) were used to estimate the kinetic parameters 
(after adjusting for the unstirred aqueous layer), the intrinsic absorption kinetics 
parameters for GlySar were Jmax = 4.0 nmol/cm
2
/sec and Km = 5.7 mM (Fig 4.5B). 
Specificity of PEPT1 Transporter 
Permeability of 10 µM GlySar was determined in the presence of various 
potential inhibitors of PEPT1 to demonstrate the specificity of transport.  As depicted in 
Fig. 4.6A, GlySar permeability in wild-type mice was significantly reduced by several 
dipeptides (GlySar, GlyPro and carnosine), the ACE inhibitor captopril, the α-amino 




amino acids (glycine and histidine), a cephalosporin without an α-amino group 
(cephazolin) and the active antiviral species acyclovir had no effect.  Moreover, in 
PEPT1 knockout mice, the potential inhibitors carnosine and cefadroxil had no influence 
on GlySar permeability.  Absence of inhibition by histidine, an inhibitor of PHT-
mediated transport, in wild-type mice suggests that PHT1 and PHT2 are not involved in 
the intestinal permeability of GlySar.   
Comparison with Rat Permeability 
Since rat is the most commonly used animal in preclinical permeability studies 
and a good correlation has already been established between rat and human permeability 
for many drugs (Amidon et al., 1988; Fagerholm et al., 1996; Chiou and Barve, 1998; 
Salphati et al., 2001; Zhao et al., 2003), the permeability of GlySar was also measured in 
this rodent species. As observed in Fig 4.7, GlySar permeability in rat was about 2x lower 





PEPT1 is believed to play an important role in the absorption of di/tripeptides and 
peptide-like drugs in small intestine.  Previous in vitro studies on PEPT1 provided us 
with important information with respect to structure-functions, substrate specificity, 
substrate affinity, mechanism of transport, and localization.  However, most studies were 
limited due to the lack of an intact blood supply, overlapping substrate specificities, and 
the contribution of multiple transport systems, thus, making it difficult to isolate the 
relative role of a single gene product, PEPT1, in relation to other possible transporters 
that are present in the small intestine.  The recent generation of PEPT1 knockout mice 
(Hu et al., 2008) has provided a unique opportunity to probe the functional activity of 
PEPT1 under physiological conditions.  In the present in situ study, we have validated the 
utility of using wild-type and PEPT1 knockout mice for intestinal perfusion by 
demonstrating the pH-stimulated uptake, specific inhibition, and low-affinity kinetics of a 
model dipeptide, GlySar.   
Human and mouse PEPT1 share many similarities, suggesting that the findings 
from mouse PEPT1 can be extrapolated to human.  At the molecular level, PEPT1 is 
highly homologous in amino acid sequence (~ 80%) across species (Liang et al., 1995; 
Miyamoto et al., 1996; Fei et al., 2000), having 83% amino acid identity between human 
and mouse PEPT1 (Fei et al., 2000).  The genomic organization of human PEPT1 also 
shows high similarity with its mouse orthologue (Urtti et al., 2001).  When expressed in 
Xenopus laevis oocytes and transfected cells, human and mouse PEPT1 share many 




membrane potential), substrate specificity, substrate affinity, and sensitivity (Liang et al., 
1995; Mackenzie et al., 1996; Fei et al., 2000).  In both species, PEPT1 transporter is 
expressed in small intestine and kidney (Liang et al., 1995; Zhang et al., 2004; Hu et al., 
2008).  With immunolocalization studies, it was demonstrated that PEPT1 is expressed in 
the apical membrane of small intestine (i.e., duodenum, jejunum and ileum), but not in 
colon for both human and mouse (Walker et al., 1998; Groneberg et al., 2001).  Gene 
expression studies have shown that mouse and human have comparative intestinal 
expression levels, whereas PEPT1 expression levels in rat were several-fold higher (Kim 
et al., 2007), suggesting that the PEPT1-mediated intestinal absorption of peptide 
substrates in human is more similar to mouse than rat.   
Although a good correlation has been established between rat and human 
permeability (Amidon et al., 1988; Fagerholm et al., 1996; Chiou and Barve, 1998; 
Salphati et al., 2001; Zhao et al., 2003), no such correlation has been determined between 
mouse and human permeability due to the sparse data available on mouse intestinal 
permeability. 
The functional characteristics of PEPT1 obtained from the current in situ model 
were in parallel with those obtained from in vitro models.  Based on a PEPT1-transfected 
cell model, PEPT1 was shown to be a low-affinity, high-capacity transporter, where Km 
for GlySar was 0.29 -0.39 mM for human PEPT1 (Liang et al., 1995; Zhang et al., 2004), 
0.35 mM for monkey PEPT1 (Zhang et al., 2004) and 1.1 mM for rat PEPT1 (Terada et 
al., 1997).  Our current in situ intestinal perfusion model reported an intrinsic Km of 5.7 
mM for GlySar in wild-type mice, which is very similar to the PEPT1 affinity of GlySar 




used here is an estimated unbiased affinity after correcting for the effect of the unstirred 
aqueous layer on GlySar permeability.   
In our concentration-dependent studies, we used GlySar concentrations up to 200 
mM since the estimated concentration of dipeptides and tripeptides after the digestion of 
protein in the intestinal lumen can be as high as 100 mM (Ganapathy et al., 2006).  The 
low-affinity and high-capacity characteristics of the PEPT1 transporter are quite suitable 
for its physiological function to absorb such a high concentration of small peptides in the 
intestinal lumen.  Previous in vitro studies have shown that human PEPT1, in addition to 
recognizing di- and tri-peptides, also recognizes peptidomimetic therapeutic agents such 
as ACE inhibitors (i.e., captopril, enalapril), β-lactam antibiotics, bestatin and the 
antiviral prodrug valacyclovir (Liang et al., 1995; Han et al., 1998; Zhang et al., 2004).  
Our findings, based on the mouse in situ intestinal perfusion model, were consistent with 
those previous results in regard to PEPT1 substrate specificity.  It is interesting to note 
that histidine, an inhibitor for PHTs, did not inhibit the permeability of GlySar suggesting 
that, despite their intestinal expression, PHT1 and PHT2 do not contribute to GlySar 
permeability at the apical surface of small intestine.  It has already been confirmed that in 
PEPT1 null nice, PEPT2, PHT1 and PHT2 are not upregulated in small intestine as a 
compensatory response to deletion of PEPT1 gene (Hu et al., 2008).   
The pH-stimulated transport of di/tripeptides has been shown for PEPT1 in rabbit, 
rat, mouse and human using several in vitro models such as intestinal brush border 
membrane vesicles (Ganapathy and Leibach, 1983; Ganapathy et al., 1984; Inui et al., 
1988), Xenopus laevis oocytes (Fei et al., 1994; Saito et al., 1995; Steel et al., 1997; Fei et 




Fujisawa et al., 2006).  In addition, uptake was shown to have a bell-shaped curve vs. pH 
with the optimal transport activity occurring at pH 5.5-6.0.  Although the optimal pH of 
GlySar permeability was observed at pH 5.5 in our in situ intestinal perfusion model, the 
magnitude of change for proton dependency was not as remarkable as shown by in vitro 
models.  The reduced effect of pH-dependent uptake was most likely due to the fact that 
changes in luminal bulk pH do not necessarily translate to significant changes in pH at 
the vicinity of the intestinal membrane where a low microclimate pH  is maintained 
(Lucas et al., 1980; Hogerle and Winne, 1983; Shiau et al., 1985).  Lucas and his 
coworkers have demonstrated that when the pH of luminal bulk phase was varied from 
5.5 to 8.5, the surface microclimate pH was only 5.5 to 6.2, a pH change less than one 
unit (Lucas et al., 1980).   
Immunoblot and immunoflourescence localization studies in rat have revealed 
that PEPT1 protein was expressed in apical membranes of the duodenum, jejunum, and 
ileum, and that the strongest staining was observed in the jejunal segment (Ogihara et al., 
1996).  Similarity, PEPT1 was also found in the apical membrane of all segments of 
mouse small intestine (i.e., duodenum, jejunum and ileum) (Groneberg et al., 2001).  
When expression patterns of PEPT1 were evaluated in human intestine, a similar finding 
was found where PEPT1 mRNA was highly expressed in small intestine with the 
expression ranking: duodenum>jejunum>ileum.  Additionally, immunoblot analyses have 
revealed that PEPT1 protein is expressed in  the duodenum, jejunum and ileum of human 
intestine (Terada et al., 2005).  In all of the studies mentioned above, PEPT1 expression 
was not found in colon.  Decreased activity of PEPT1 in ileum, compared to jejunum, is 




ileum than jejunum (Silk et al., 1976) suggesting a gradual decrease in the concentration 
of small peptides while the concentration of single amino acids increase as luminal 
contents move along the intestine.  Interestingly, expression of the amino acid transporter 
B
0
AT1 (SLC6A19) also increases from duodenum to ileum (Terada et al., 2005).  The 
reciprocal expression of PEPT1 and B
0
AT1, and the increased activity of brush border 
membrane peptidase from the jejunum to ileum may play an important role in 
maintaining the efficient absorption of end products from a protein meal. 
In conclusion, in the present study we have demonstrated that 1) PEPT1 is 
responsible for at least 90% of dipeptide uptake in the small intestine; 2) that PEPT1 
exhibits a pH-stimulated uptake of dipeptide; 3) that the inhibition of dipeptide uptake is 
specific; 4) that transport of GlySar exhibited low-affinity kinetics, which is reflective of 
PEPT1 transport kinetics.  Taken together, these results suggest that PEPT1 will play a 
crucial role in the uptake of dietary peptides, mimetics and peptide-like drugs in the small 
intestine.  Future studies will focus on elucidating the role of PEPT1 in the regional 
permeability of peptide-like therapeutic drugs/prodrusg such as cefadroxil and 




































Figure 4.1  Effective permeability (Peff) of 10 µM [
3





 mice. Studies were performed in pH 6.5 perfusion buffer.  Data 










































Figure 4.2  Effective permeability (Peff) of 10 µM [
3





 mice. Studies were performed in pH 6.5 perfusion buffer.  








































Figure 4.3  Effective permeability (Peff) of 10 µM [
3





 mice. Studies were performed in pH 6.5 perfusion 







































































































Figure 4.4  Effect of pH on effective permeability (Peff) of 10 µM [
3
H]GlySar during 
jejunal perfusion of wild-type (+/+) mice (A) and PEPT1 null (-/-) mice (C).  * p < 0.05, 
compared to pH 7.4.  Effect of dimethylamiloride (DMA) (B) on the Peff of 10 µM 
[
3
H]GlySar during jejunal perfusion of wild-type mice.  Studies were performed in pH 
































































Figure 4.5  Concentration-dependent flux of [
3
H]GlySar (0.01-20 mM total substrate in 
perfusate) during jejunal perfusion of wild-type mice.  Studies were performed in pH 6.5 
buffer (n=4, mean ± SE).  In panel A, Cin represents perfusate concentration of GlySar.  












































































































































Figure 4.6  Effect of potential inhibitors (25 mM) on the Peff of 10 µM [
3
H]GlySar during 
jejunal perfusion of wild-type (+/+) mice (A) and PEPT1 null (-/-) mice (B).  Studies 
were performed in pH 6.5 perfusion buffer (n=4, mean ± SE).   ** p < 0.01, compared to 





































Figure 4.7  Effective permeability (Peff) of 10 µM [
3
H]GlySar during jejunal perfusion of  
mice and rats.  Studies were performed in pH 6.5 perfusion buffer.  Data are presented as 
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Chapter 5  
 
SIGNIFICANCE OF PEPT1 ON THE IN VIVO ORAL 
ABSORPTION AND DISPOSITION OF 
GLYCYLSARCOSINE IN WILD-TYPE AND PEPT1 
KNOCKOUT MICE 
ABSTRACT 
Purpose. Genetically-modified mice have become a useful tool to elucidate the function 
and significance of specific proteins in the body. Although the proton-oligopeptide 
cotransporter PEPT1 (SLC15A1) is known to transport a variety of peptides, 
peptidomimetics and peptide-like drugs, its relative importance in intestinal absorption in 
vivo is unknown. Thus, this study examined the dose-dependent absorption profiles of a 
model dipeptide, glycylsarcosine (GlySar), in Pept1
+/+
 (WT) and Pept1
-/-
 (KO) mice, 
along with its tissue distribution.   
Methods.  [
3
H]GlySar was administered by gavage to WT and KO mice at doses of 1, 
10, 100, 1000, and 5000 nmol/g body weight. Blood samples were obtained serially over 
480 min, the plasma harvested, and area under the plasma concentration-time curve 
(AUC) determined. Tissue distribution studies were also performed where samples were 








C]Dextran MW 70,000 (0.15 μCi/mouse) was administered by tail vein injection 5 min 
prior to harvesting the tissues to correct for vascular space.   
Results.  For all five doses, the systemic exposure (AUC) of GlySar was about 50% 
lower in KO mice than in WT animals (p < 0.01). With respect to the absorption profile 
in KO mice, plasma levels of GlySar reached a plateau at 90 min and then rose to a 
second plateau at 240 min. In WT mice, the plasma levels rose continuously to reach a 
single plateau at 90 min.  When partial AUC (0-120min) was used as an indicator of rate 
of absorption, there was a 60% reduction in rate of GlySar absorption in KO mice 
compared to WT animals.  A linear correlation was also observed between AUC and dose 
for both genotypes in the dose ranges of 1-100 nmol/g.  Tissue accumulation of GlySar 
was significantly lower in KO versus WT mice.  However, when tissue concentrations of 
GlySar were corrected for corresponding plasma levels, no statistical differences were 
observed, except for intestine.  
Conclusions. PEPT1 ablation significantly reduced the rate and extent of in vivo oral 
absorption of GlySar in KO mice as compared to WT animals.  With the exception of 





Following the ingestion of dietary protein (70-100 g per day), proteins are 
converted into large peptides by gastric and pancreatic proteases in the gastrointestinal 
lumen followed by a further hydrolysis into small peptides (80%) and free amino acids 
(20%) by various peptidases in the brush border membrane of intestinal epithelium 
(Ganapathy et al., 2006).  The final end products of protein digestion are absorbed into 
the enterocytes predominately in the form of di- and tripeptides as supposed to free amino 
acids (Matthews, 1975).  Once inside the enterocytes, the majority of the di- and 
tripeptides undergo further hydrolysis into their constituent amino acids by cytoplasmic 
peptidases and exit the epithelial cells via different basolateral amino acid transporters.  A 
small amount of di- and tripeptides that are resistant to cytoplasmic peptidases exit the 
enterocytes intact across the basolateral membrane through a basolateral peptide 
transporter that has yet to be cloned (Terada et al., 1999).   
PEPT1, a member of proton-coupled oligopeptide transporter (POT) family (i.e., 
PEPT1, PEPT2, PHT1 and PHT2) is an electrogenic symporter that translocates small 
peptides/mimetics along with protons across a biological membrane via an inwardly-
directed proton gradient and negative membrane potential  (Herrera-Ruiz and Knipp, 
2003; Daniel and Kottra, 2004).  PEPT1 is strongly expressed on the apical membrane of 
enterocytes in the small intestine (i.e., duodenum, jejunum, and ileum) with little or no 
expression in normal colon (Ogihara et al., 1996; Walker et al., 1998; Groneberg et al., 
2001).  In addition to PEPT1, human and rat small intestine have been shown to express 




villous epithelium of small intestine (Bhardwaj et al., 2006).  However, PEPT1 is 
believed to be the primary POT responsible for small intestinal absorption of 
di/tripeptides and peptide-like therapeutic agents.  PEPT1 is characterized as a high-
capacity, low-affinity transporter.  It was first isolated and cloned from a rabbit  intestine 
cDNA library (Fei et al., 1994), which subsequently lead to the cloning of PEPT1 from 
human (Liang et al., 1995), rat (Saito et al., 1995; Miyamoto et al., 1996) and mouse (Fei 
et al., 2000) intestinal cDNA libraries.  It has been found that PEPT1 is highly 
homologous across species (~ 80%) (Liang et al., 1995; Miyamoto et al., 1996; Fei et al., 
2000).  PEPT1 is predicted to contain 12 transmembrane domains with both C and N 
terminals facing the cytosolic side, and protein sizes ranging from 707 to 710 amino acids 
depending on the species.  The genomic organization of human PEPT1 shows high 
similarity with its mouse orthologue (Urtti et al., 2001).  In addition, studies suggest that 
mouse and human have comparable intestinal expression patterns and levels, whereas 
PEPT1 expression level in the rat is several fold higher (Kim et al., 2007).  PEPT1, in 
addition to transporting di- and tripeptides, also transports a number of peptidomimetic 
therapeutic agents with different conformations, size, polarity and charge (e.g., β-lactam 
antibiotics, ACE inhibitors, renin inhibitors, bestatin, and antiviral prodrug valacyclovir), 
and acts as a vehicle for their effective intestinal absorption.  Due to its broad substrate 
specificity and high capacity, PEPT1 is considered to be a very attractive target for drug 
delivery to improve the bioavailibility of low permeable drugs.   
PEPT1, in addition to be highly expressed in small intestine, is also expressed in 
apical membrane of S1 segments of the kidney proximal tubule (i.e., kidney cortex), 




the low-capacity, high-affinity peptide transporter PEPT2 that is localized in the brush 
border of S3 segments in proximal tubule (i.e., outer stripe of outer medullar) (Liu et al., 
1995; Shen et al., 1999; Rubio-Aliaga et al., 2000).  In spite of the sequential expression 
of PEPT1 and PEPT2 in renal proximal tubules, studies have definitively shown that 
PEPT2 accounts for the vast majority of reabsorption for the model dipeptide 
glycylsarcosine (GlySar) and the β-lactam antibiotic cefadroxil in kidney (Takahashi et 
al., 1998; Inui et al., 2000; Ocheltree et al., 2005; Shen et al., 2007).  PEPT1 is also 
expressed in other tissues such as liver, pancreas, lung, bile duct, ovary, placenta, testis, 
and prostate (Fei et al., 1994; Liang et al., 1995; Knutter et al., 2002; Lu and Klaassen, 
2006), suggesting a possible role of PEPT1 in disposition of small peptide/mimetics in 
those tissues.  Using immunoflourescence microscopy and transport studies, PEPT1 was 
demonstrated to be expressed in the lysosomal membrane of liver cells (Thamotharan et 
al., 1997), renal cells (Zhou et al., 2000), and pancreatic cells (Bockman et al., 1997), 
rather than being exclusively confined to the plasma membrane.   
Due to the physiological and pharmacological importance of PEPT1 in the 
absorption of di/tripeptides and peptidomimetic drugs in the small intestine, PEPT1 is the 
most extensively studied transporter among the POT members.  However, the previous 
studies were based on non-physiological in vitro models that lack an intact blood supply.  
In addition, PEPT1 is also expressed in other tissues such as kidney, lung, and liver 
where multiple POT members are expressed with overlapping substrate specificities, thus 
confounding an accurate assessment of PEPT1’s significance in these tissues.  Utilizing 
PEPT1 deficient mice will offer a powerful tool to assess the relative importance of 




intestine as well as disposition in other tissues.  Previously, we have investigated the role 
of PEPT1 in the absorption of small peptides by evaluating the in situ intestinal 
permeability of GlySar in wild-type and PEPT1 knockout mice, and have found that 
PEPT1 is responsible for at least 90% of dipeptide uptake in the small intestine (Chapter 
4).  However, results from the in situ intestinal perfusion model may not necessarily 
reflect what actually occurs in vivo where gastric emptying, intestinal transit, and 
intestinal residence time may influence the rate and extent of oral absorption.  Therefore, 
the aim of the present study is to delineate the relative importance of PEPT1 in the in vivo 
absorption and disposition of small peptide/mimetic substrates by using glycylsarcosine 
(GlySar) as a model compound in PEPT1
+/+
 (wild-type) and PEPT1
-/-









H]GlySar (14.4 Ci/mmol), [
14





C]dextran-carboxyl 70,000 (1.1 mCi/g) were obtained from Moravek 
Biochemicals and Radiochemicals (Brea, CA).  Unlabelled GlySar (mol. wt. = 146.1) 
was supplied by Sigma-Aldrich (St. Louis, MO).  Hyamine hydroxide was purchased 
from ICN Radiochemicals (Irvine, CA) and hydrogen peroxide was obtained from 
Sigma-Aldrich (St. Louis, MO).  All other chemicals were acquired from standard 
sources. 
Animals 
Animal studies were carried out in accordance with the Guide for the Care and 
Use of Laboratory Animal as adopted and promulgated by the U.S National Institutes of 
Health.  Gender matched 8-10 week old PEPT1
+/+
 (wild-type) and PEPT1
-/-
 (null) mice 
were used for all experiments.  The mice were kept in temperature controlled 
environment with a 12-h light and 12-h dark cycle, and received a standard diet and water 
ad libitum (Unit for Laboratory Animal Medicine, University of Michigan, Ann Arbor, 
MI). 





mice were fasted overnight prior to each experiment.  The 




Gastric gavage (20G needle) was used to orally administer a solution of [
3
H]GlySar (0.5 
µCi/g body weight, 10 μl/g body weight) for all doses.  Serial blood samples (Peng et al., 
2009) were collected by tail nicks at 0.5, 5, 10, 20, 30, 45, 60, 75, 90, 120, 180, 240, 360, 
and 480 min after the initial oral dose.  The blood samples (~ 20 µL) were transferred to a 
0.2 ml thin walled PCR tube containing 3 µl of 7.5% potassium EDTA and centrifuged at 
3300 g for 3 min at ambient temperature to obtain the plasma.  5-10 µl of plasma was 
transferred into a scintillation vial, and 6 mL of CytoScint scintillation fluid (MP 
Biomedicals, Solon, OH) was added to the plasma sample.  The radioactivity of plasma 
sample was measured with a dual-channel liquid scintillation
 
counter (Beckman LS 6000 
SC; Beckman Coulter Inc., Fullerton, CA).  Animals were returned to their cages in 
between blood sampling where they had free access to water.  Food was provided in their 
cages four hours after the initial dose.  The cage was equipted with heating pad to 
maintain the mice body temperature.  After 1 and 4 h of oral gavage, 250 µL of warm 
saline was given by I.P as the supplemental fluid in order to prevent dehydration.   
After the last blood sample was obtained (8 h), several organs/tissues (e.g., 
kidney, liver, lung, pancreas, spleen, small
 
and large intestines, bile ducts, ovary, testis, 
prostate, skeletal muscle, heart, eye, and cerebral cortex) were collected.  One kidney was 
collected intact, and the other kidney was separated into renal cortex, outer medulla, and 
inner medulla.  The small intestine was cut into duodenum, proximal jejunum, mid-small 
intestine, distal ileum, proximal colon, and distal colon; each segment was washed with 
pre-warmed saline solution to remove the fecal material and then blotted dry prior to 
weighing.  A larger blood volume (30 µL) was collected at the end of experiment to 




concentration.  Tissue samples were then solubilized in 0.5 ml of 1 M hyamine hydroxide 
(tissue solubilizer) (ICN Radiochemicals, Irvine, CA) for 24 h at 37
o
C.  After the tissue 
solubilization, 40 μl hydrogen peroxide (30 wt%) (Sigma Aldrich, St. Louis, MO) was 
added to each sample for color treatment and incubated at 37
o
C for 24 h.  A 6 mL aliquot 
of CytoScint scintillation fluid (MP Biomedicals, Solon, OH) was added to the tissue and 
blood samples, and the radioactivity of each sample was measured with a dual-channel 
liquid scintillation
 
counter.  At 5 min prior to tissue harvesting, [
14
C]dextran MW 70,000 
(0.15 μCi/mouse) was administered via tail vein injection to determine the vascular space 
of tissues, and all tissue concentrations of GlySar were corrected for this values.   
Corrected tissue concentrations of GlySar (Ctiss.corr, nmol/g wet tissue) were 
calculated (Ocheltree et al., 2005; Shen et al., 2007) as: 
 
where Ctiss is the uncorrected GlySar tissue concentration (nmol/g wet tissue), V is the 
vascular space determined by dextran in the tissue (ml/g), and Cb is the GlySar blood 
concentration (nmol/ml). 
A separate tissue distribution study was also performed after orally dosing [
3
H] 
GlySar by gavage at 10 nmol/g body weight (0.5 µCi/g body weight, 10 μl/g body 
weight).  However in this study, organ/tissue and blood samples were collected one hour 
after the initial dose.  All other aspects of sample treatment and analysis were described 
previously. 








 mice were fasted overnight prior to each experiment.  The 
drug was dissolved in normal saline and administered to the mice in aqueous solution.  
The animals were anesthetized with sodium pentobarbital (40-60 mg/kg, i.p.).   Following 
anesthesia, the mice were given [
3
H]GlySar (10 nmol/g body weight, 0.25 µCi/g body 
weight) via tail vein injection (5 μl/g body weight).  Serial blood samples (Peng et al., 
2009) were collected by tail nicks at 0.25, 2, 5, 15, 30, 60, 120, 180, 240, 360, and 480 
min after the initial intravenous bolus dose.  The blood samples (~ 20 µL) were 
transferred to a 0.2 ml thin walled PCR tube containing 3 µl of 7.5% potassium EDTA 
and centrifuged at 3300 g for 3 min at ambient temperature to obtain the plasma.  5-10 µl 
of plasma was transferred into a scintillation vial, and 6 mL of CytoScint scintillation 
fluid was added to the plasma sample.  The radioactivity of plasma sample was measured 
with a dual-channel liquid scintillation
 
counter.  Animals were returned to their cages in 
between blood sampling where they had free access to water.  Food was provided in their 
cages four hours after the initial dose.  The cage was equipted with a heating pad to 
maintain the mice body temperature.  After 1 and 4 h of I.V administration, 250 µL of 
warm saline was given by I.P as the supplemental fluid in order to prevent dehydration.  
After the last blood sample was obtained (8 h), several organs/tissues were collected, as 
described previously (Systemic Exposure of Orally Administered GlySar). 





mice were fasted overnight prior to the each experiment.  
The drug was dissolved in normal saline and administered to the mice in aqueous 
solution.  Gastric gavage (20G needle) was used to orally administer a solution of 
[
14




mouse was placed separately in a Nalgene metabolic cage with diuresis adapter (Harvard 
Apparatus Inc., Holliston, MA) for 24 h, where they have free access to water.  Food was 
provided in their cages four hours after the initial oral dose.  Urine samples were 
collected at 8 and 24 h.  The urine samples were centrifuged at 15,000 g for 10 min at 
room temperature, and the supernatants were then frozen at -80
o
C until analysis by high-
performance liquid chromatography (HPLC).  Prior to HPLC analysis, the urine samples 
were diluted 2-fold in water, then analyzed by HPLC (Model 515 Pump, Water, Milford, 
MA) with radiochromatographic detection (Flo-One 500TR, PerkinElmer Life and 
Analytical Sciences, Boston, MA).  Sample components were separated using a reversed-
phase column (Supelco Discovery® C-18, 5 μm, 250 cm × 4.6 mm, Supelco Park, 
Bellefonte, PA) subjected to a mobile phase of 0.01 M phosphate buffer (pH = 2.0) and 
0.1% heptafluorobutyric acid, pumped isocratically at 1 ml /min under ambient 
temperature.  Retention times for glycine and GlySar were 4.8 min and 9.8 min, 
respectively, under ambient conditions.  Stability of GlySar was determined by its 





Data are reported as mean ± SE, unless otherwise noted.  Statistical differences 
between the wild-type and PEPT1 null mice were determined using a two sample 
student’s  t-test; for multiple comparisons, one-way variance of analysis (ANOVA) was 
performed followed by Dunnett’s test for pairwise comparison with the control group 
(GraphPad Prism, v4.0; GraphPad Software, Inc., La Jolla, CA). p < 0.05 was considered 






Dose Dependency of Orally Administered GlySar 
In order to probe whether PEPT1 deletion had any effect on the in vivo oral 
absorption of small peptides, GlySar was administered orally over the dose rage of 1 to 
5000 nmol/g body weight to wild-type and PEPT1 knockout mice (Figs 5.1-5.5).  Since it 
takes approximately 20-30 min for the ingested luminal contents  to move 50% of the 
small intestine length in mouse (Nagakura et al., 1996; Pol et al., 1996; Nagakura et al., 
1997; El-Salhy, 2001), and the entire gastrointestinal transient time in mouse is 
approximately 150-200 min (Nagakura et al., 1996; Nagakura et al., 1997; Schwarz et al., 
2002; Friebe et al., 2007; Yamamoto et al., 2008), the oral absorption profiles of GlySar 
were examined at 120 min, 240 min, and 480 min.  With respect to the absorption profile 
in wild-type mice, GlySar plasma levels rose rapidly and reached a single plateau level at 
about 90 min for the 1, 10, 100, and 1000 nmol/g doses, and at about 30 min for the 5000 
nmol/g dose (Figs 5.1-5.5).  For PEPT1 null mice, GlySar plasma levels reached a first 
plateau at about 90 min and then rose to a second plateau at about 240 min for all 5 doses.  
As demonstrated in Figs 5.1-5.5, the extent of oral systemic exposure of GlySar was 
significantly reduced in PEPT1 null mice compared to wild-type mice (especially during 
the first 2 h) for all tested doses (p<0.01).  The extent of GlySar absorption in PEPT1 null 
mice is approximately 40%, 55% and 70% of that achieved in the wild-type during the 2, 
4, and 8 h absorption profile periods, respectively, for all 5 doses (Table 5.1), suggesting 




GlySar was administered orally over a 5000-fold dose range to explore whether or 
not there is saturation of the PEPT1 transporter.  Dose-corrected AUCs (area under the 
plasma concentration-time curve) at different doses were compared with 1 nmol/g dose as 
a control (ANOVA followed by Dunnett’s test for pairwise comparison).  As 
demonstrated in Fig 5.6, there is dose linearity over doses of 1-100 nmol/g for both 
genotypes.  At doses of 1000 and 5000 nmol/g, dose-corrected AUCs decreased in the 
same direction for both genotypes, although they have some statistical differences for 
different AUC calculations.  There were 13-20% and 25-35% reductions in dose-
corrected AUC values at doses of 1000 and 5000 nmol/g, respectively, when compared to 
the 1 nmol/g dose for both genotypes.  However, reductions in the extent of absorption at 
both doses are most likely due to GlySar precipitation in the gastrointestinal tract, 
because of rapid water absorption in the jejunum (Masaoka et al., 2006), as opposed to 
PEPT1 saturation.  We have observed that at the 10,000 nmol/g dose, GlySar had 
solubility issues in solution (data not shown).  
As a method to illustrate potential differences in absorption rate between 
genotypes, cumulative partial AUC vs. time profiles for the 5 doses of GlySar are shown 
in Figs 5.7-5.11.  As observed in the graphs, for wild-type mice, the curve had a single 
slope from 20 to 480 min.  However, for PEPT null mice, the curves had 2 distinct slopes 
from 20 to 480 min; a slower slope was observed from 20-120 min and a faster slope was 
observed from 240-480 min, which was parallel to that of wild-type mice.  The transition 
point for the two slopes in PEPT1 null mice appears to be at about 180 min.  As shown in 
Table 5.2, at 20-120 min, there was approximately a 60% reduction in slope in PEPT1 




null mice was very similar to that of wild-type (< 10% difference).  We believe these 
differing slopes represent absorption rate differences between genotypes over the first 2 h 
followed by  similar disposition profiles at later times for PEPT1 null and wild-type mice.   
Overall, results from the oral studies suggest that deletion of PEPT1 significantly 
reduces the rate and extent of oral GlySar absorption during in vivo conditions, which is 
consistent with the findings from in situ model (Chapter 4).  A linear correlation was also 
observed between AUC and dose for both genotypes in the dose range of 1-100 nmol/g.     
Systemic Exposure of Intravenously Administered GlySar 
Fig 5.12 depicts the plasma-concentration profile of GlySar in wild-type and 
PEPT1 null mice after an i.v. bolus administration of dipeptide at 10 nmol/g dose.   As 
demonstrated, there is a very rapid initial decline in plasma concentration (0-120 min) 
followed by an extremely slow terminal disposition phase (120-480 min) for both 
genotypes.  The very slow terminal phase could be due to a very efficient reabsorption of 
GlySar via peptide transporters in kidney (PEPT1 and/or PEPT2) resulting in prolonged 
recirculation of dipeptide in the body.  Notwithstanding the mechanism, the very slow 
terminal phase precluded an accurate estimate of GlySar terminal half-life and AUC(0-inf), 
along with model fitting of the data.  Therefore, AUC values were determined 
noncompartmentally for the experimental data observed.  
Tissue Distribution of GlySar 
Due to the expression of PEPT1 in many tissues, in addition to its presence in 




administration in wild-type and PEPT1 null mice.  Fig 5.13 displays the concentration of 
GlySar in selected tissues 60 min following an oral dose.  Comparison of GlySar tissue 
concentration in PEPT1 null mice to wild-type mice shows that PEPT1 has a major 
impact on tissue accumulation of GlySar.  In particular, wild-type mice had about 7-fold 
higher tissue accumulation of GlySar in duodenum compared to PEPT1 null mice.  
Tissue concentrations of GlySar in other tissues were 2 to 4 fold greater in wild-type 
mice than PEPT1 null mice (Fig 5.13 A).  Since the plasma concentrations of GlySar 
were significantly different between the two genotypes at 60 min (Fig 5.2), the source of 
GlySar for all tissues except the intestine after oral dosing, the tissue concentrations of 
dipeptide were corrected by their corresponding plasma concentrations for all tissue other 
than intestine in order to rule out differences being due to systemic exposure alone (Fig 
5.13B).  No statistical differences were observed between genotypes in the tissue/plasma 
concentration ratios of GlySar for all tissues (Fig 5.13 B).   
Tissue accumulation of GlySar was also evaluated 8 h after both oral and i.v. 
bolus administrations.  When administered orally, GlySar accumulation was 9.4-fold 
(p<0.001) and 1.5-fold (p<0.5) higher in duodenum and distal ileum, respectively, in 
wild-type mice compared to PEPT1 null mice, demonstrating the functional role of 
PEPT1 in the small intestine (Fig 5.14A).  No statistical differences were observed in all 
other tissues between the two genotypes (Fig 5.14A).  When tissue accumulation of 
GlySar was corrected by its corresponding plasma level for all tissues (intestine omitted), 
no statistically significant differences between the genotypes were observed either (Fig 
5.14B).  The consistency between the tissue concentration and tissue/plasma 




similarity in GlySar plasma concentrations in the two genotypes at 8 h after the oral 
gavage (Fig 5.2C).  When GlySar was administered by i.v. bolus, wild-type mice had 
about 1.3 to 9.6 times greater tissue accumulation of dipeptide in selected tissues (i.e., 
testis, pancreas, heart, small and large intestine, skeletal muscle, eyes, and cerebral 
cortex) compared to PEPT1 null mice (Fig 5.15A).  When the tissue concentration of 
GlySar was normalized by its corresponding plasma level for all tissues including 
intestine, no statistically significant differences between the genotypes were observed, 
except for mid small intestine (p< 0.05) (Fig 5.15B).   
Metabolic Stability of GlySar 
Metabolic stability of GlySar following oral gavage administration was evaluated 
by high-performance liquid chromatography with radiochemical detection, coupled to 
liquid scintillation counting spectrometry.  At 8 h following the oral administration, 85% 
and 80% of GlySar was recovered intact in the urine for wild-type and PEPT1 null mice, 
respectively (Fig 5.16A).  Approximately 77% of GlySar was recovered in the urine 
intact 24 h after dosing for the genotypes (Fig 5.16B).  No statistical differences were 
observed between the two genotypes for GlySar stability.  Therefore, GlySar instability 
was not a confounding issue in these studies, and no further correction of the data was 
performed.   
Previously in our laboratory, we investigated the stability of GlySar following an 
i.v. bolus dose of dipeptide and demonstrated that 95% of GlySar was recovered in the 
urine intact 24 h after dosing for wild-type mice (Ocheltree et al., 2005).  The difference 




after 24 h suggests a possible metabolism of GlySar in the gastrointestinal tract (e.g., 
brush border membrane peptidase, enterocyte cytoplasmic peptidases).  





PEPT1 is believed to play an important role in the absorption of di/tripeptides, 
peptidomimetics and peptide-like drugs in the intestine.  Previous in vitro studies 
provided important information with respect to PEPT1 structure-function, substrate 
specificity, substrate affinity, mechanism of transport, and localization.  However, most 
studies were often limited due to a lack of intact blood supply, overlapping substrate 
specificities, and contribution of multiple transport systems, thus, making it difficult to 
isolate the relative role of a single gene product (i.e., PEPT1) in relation to other possible 
transporters that are present in the small intestine.  The recent generation of PEPT1 
knockout mice (Hu et al., 2008) has provided a unique opportunity to probe the 
functional activity of PEPT1 under physiological and pathophysiological conditions.  
Previously, we have investigated the role of PEPT1 in dipeptide (i.e., GlySar) absorption 
using an in situ intestinal perfusion model and found that PEPT1 is responsible for at 
least 90% of dipeptide uptake in the small intestine (Chapter 4).  Although the in situ 
intestinal perfusion model may be reflective of in vivo physiological conditions following 
an oral administration (i.e., intact blood supply, preserved microclimate, brush border 
enzymes, and transporters) and is widely used in preclinical settings to predict human 
drug absorption, it also has many limitations (e.g., not having an appropriate intestinal 
residence time, lacking intestinal motility, and perfused drug not traveling through the 
whole length of intestine), thus limiting the extrapolation of its finding to the in vivo 
setting.  As a result, we have attempted to confirm our findings from the in situ model 
with in vivo studies.  By using PEPT1 knockout mice under physiological in vivo 




rate and extent of in vivo oral absorption of GlySar in PEPT1 knockout mice as compared 
to wild-type animals.  Moreover, with the exception of small intestine, PEPT1 does not 
appear to affect the systemic tissue distribution of GlySar. 
Human and mouse PEPT1 share many similarities, suggesting that the findings 
from mouse PEPT1 can be extrapolated to human.  At the molecular level, PEPT1 is 
highly homologous in amino acid sequence (~ 80%) across species (Liang et al., 1995; 
Miyamoto et al., 1996; Fei et al., 2000), having 83% amino acid identity between human 
and mouse PEPT1 (Fei et al., 2000).  The genomic organization of human PEPT1 also 
shows high similarity with its mouse orthologue (Urtti et al., 2001).  When expressed in 
Xenopus laevis oocytes and transfected cells, human and mouse PEPT1 share many 
molecular dynamic similarities with respect to their driving force (i.e., pH gradient and 
membrane potential), substrate specificity, substrate affinity, and sensitivity (Liang et al., 
1995; Mackenzie et al., 1996; Fei et al., 2000).  In both species, the PEPT1 transporter is 
expressed in small intestine and kidney (Liang et al., 1995; Zhang et al., 2004; Hu et al., 
2008).  With immunolocalization studies, it was demonstrated that PEPT1 is expressed in 
the apical membrane of small intestine (i.e., duodenum, jejunum and ileum), but not in 
colon for both human and mouse (Walker et al., 1998; Groneberg et al., 2001).  Gene 
expression studies have shown that mouse and human have comparative intestinal 
expression levels, whereas PEPT1 expression levels in rat were several-fold higher (Kim 
et al., 2007), suggesting that the PEPT1 mediated intestinal absorption of peptide 
substrates in human is more similar to mouse than rat.   
In the current study, we administered GlySar over a 1-5000 nmol/g dose range, 




Ganapathy et. al. (2006), the estimated concentration of dipeptides and tripeptides after 
the digestion of protein in the intestinal lumen can reach as high as 100 mM.  In the 
present study, the volume of oral gavage was 200 μl/20 g body weight at every dose.  
Studies by McConnell and coworkers (2008) have suggested that the water content of 
mouse gastrointestinal tract is approximately 0.4 g, which would correspond to 0.4 ml 
(assuming 1 g/ml density approximation).  Thus, with an average body weight of 20 
g/mouse, current doses of 1, 10, 100, 1000 and 5000 nmol/g of GlySar would 
approximate  to 0.033, 0.33, 3.3, 33, and 167 mM, respectively, in the small intestine.   
Absorption in the intestine is influenced by many factors including the intrinsic 
permeability of compounds, surface area of the intestinal membrane, drug concentration 
in the intestinal lumen, pore radius for paracellular pathways, thickness of the mucus 
layer, membrane fluidity that affects the passive permeability, and the gastrointestinal 
transit time that controls the residence time of the compound in the intestine (Masaoka et 
al., 2006).  Among these factors, permeability through the membrane, luminal drug 
concentration, and residence time are considered the most important factors for oral drug 
absorption (Kimura and Higaki, 2002; Masaoka et al., 2006).  Luminal drug 
concentration following oral administration changes due to its absorption in each 
intestinal segment as well as because of changes in fluid volume of each intestinal 
segment.  In wild-type mice, the concentration of GlySar probably decreases rapidly as it 
travels through the intestine due to a rapid absorption via PEPT1.  As a result, we might 
not observe a noticeable saturation of PEPT1 even at a high oral dose of 1000 or 5000 
nmol/g (equates to 33 and 167 mM, respectively) which are estimated to be above the Km 




19 mM for GlySar in mouse in situ intestinal perfusion model, Chapter 4).  In contrast, in 
PEPT1 knockout mice, due to the lack of GlySar absorption via PEPT1, higher 
concentrations of GlySar might become available at later intestinal segments, thus having 
higher driving force for passive permeability in these regions than in wild-type.  The 
increased role of passive permeability at the later intestinal segments might explain the 
second rise in GlySar plasma concentrations from 120-240 min in PEPT1 null mice (Figs 
5.1-5.5).   
We believe that the reduction in dose-corrected AUCs in both genotypes at 1000 
and 5000 nmol/g doses (Fig 5.6) are most likely due to the precipitation of GlySar in the 
gastrointestinal tract because of rapid water absorption in the jejunum, especially in 
PEPT1 null mice.  If it was only due to saturation of the PEPT1 transporter, we would not 
have observed a similar reduction in dose-corrected AUCs in PEPT1 knockout mice.  
Masaoka and coworkers (2006) have reported that for a poorly permeable compound, 
drug concentrations in the small intestine could get 2-5 fold higher than the administered 
dose concentration due a quick absorption of ingested water in the jejunum.  This 
phenomenon could be the case in PEPT1 null mice at high GlySar concentrations (i.e., 
1000 and 5000 nmol/g doses), resulting in precipitation of GlySar and, consequently, a 
reduction in the dose-corrected AUCs.  In wild-type mice, the reduction in dose-corrected 
AUCs at 1000 and 5000 nmol/g doses could be due to a combined effect of GlySar 
precipitation at those doses (because of a rapid water absorption) and partial saturation of 
PEPT1 transporter.   
Although there is general consensus about using AUC as an indicator of extent of 




Cmax, tmax, and partial AUC (Chen et al., 2001).   Among these, partial AUC has been 
suggested to be a more sensitive measure of absorption rate than Cmax and/or  tmax (Chen, 
1992).  In the current study, the ratio of AUC0-8h of PEPT1 knockout mice to wild-type 
mice is about 0.7-0.75 (Table 5.1, Figs 5.1-5.5), suggesting a 25-30% decrease in extent 
of GlySar absorption due to PEPT1 deletion.  When partial AUCs (0-2 h) were compared 
as a mean of assessment of rate of absorption, there was a 60% reduction in absorption 
rate of GlySar due to deletion of PEPT1 (Table 5.1, Figs 5.1-5.5).   When incremental 
accumulative partial AUC was plotted versus time, there was a 60% decrease in the slope 
(0-2 h) of the plot in the PEPT1 null mice compared to that of wild-type (Table 5.2, Figs 
5.7-5.11), again suggesting an approximately 60% reduction in rate of GlySar absorption 
due to the deletion of PEPT1 transporter.  However, when rates of accumulative partial 
AUC increase were compared at 240-480 min, the two genotypes had very similar slopes, 
suggesting a similar disposition profile at these later time points.   
When GlySar was administered by i.v. bolus, there was an exceptionally slow 
terminal elimination phase (120-480 min) for both wild-type and PEPT1 null mice (Fig 
5.12).  The very slow terminal elimination phase could be due to an efficient reabsorption 
of GlySar via peptide transporters in kidney (PEPT1 and/or PEPT2) causing a 
recirculation of dipeptide in the body.  When GlySar plasma levels are compared between 
wild-type and PEPT1 null mice, there is a 25% reduction in GlySar plasma level in 
PEPT1 knockout mice in terminal phase (120-480 min) compared to wild-type mice (Fig 
5.12).  The slow terminal phase could be due to a number of other factors such as 
reabsorption of GlySar in kidney by processes other than PEPT1/PEPT2 and 




The relative importance of PEPT1 was quite dramatic during in situ single-pass 
perfusions of GlySar in jejunal tissue, in which a > 90% reduction in GlySar permeability 
was observed in PEPT1 knockout mice compared to wild-type mice (Chapter 4).  
Although the current in vivo studies corroborate the in situ findings, the magnitude of 
PEPT1’s relevance was much smaller during the in vivo studies, in which an approximate 
50% reduction in the extent of GlySar absorption was observed in PEPT1 null mice 
compared to wild-type mice over 8 h (Table 5.1).  Other mechanisms (e.g., passive 
permeability, paracellular permeability) may play a bigger role in the in vivo absorption 
of GlySar than previously believed.  A possible compensatory response to deletion of 
PEPT1 by up-regulation of PEPT2, PHT1 and PHT2 has already been ruled out during 
the initial development and validation of PEPT1 deficient mice (Hu et al., 2008).  The 
difference we observed between the in situ and in vivo conditions may reflect the residual 
length of the entire intestine such that the longer residence time of a drug may increase its 
passive permeability, thereby, diminishing the role of the active transporter PEPT1.  
Additionally, passive permeability might play an even larger role in the absence of 
PEPT1 transport in the null mice.  This speculation is in agreement with the findings 
from Hironaka and coworkers’ (2009) where PEPT1 contributed to one-half of total 
absorption of cephalexin and its function was compensated by passive diffusion if PEPT1 
does not function properly.  
In conclusion, the current study demonstrates that ablation of PEPT1 significantly 
reduced the in vivo rate and extent of oral absorption of dipeptides (i.e., GlySar) in 
PEPT1 null compared to wild-type mice following an oral administration.  However, the 




as remarkable as previously thought based on in vitro and in situ models.  Other than 
small intestine, PEPT1 does not appear to affect the tissue distribution of GlySar.   
Further studies will be directed at understanding the effect of PEPT1 on the oral 
absorption of peptidomimetic therapeutic agents such as cefadroxil and valacyclovir 
during in vivo conditions.  In addition, the effect of PEPT1 deletion on intestinal motility, 



















































































































Figure 5.1  Plasma concentrations of GlySar as a function of time over 120 min (A), 240 
min (B), and 480 min (C) in PEPT1
+/+
 (wild-type) and PEPT1
-/-
 (KO) mice following a 1 





















































































































Figure 5.2  Plasma concentrations of GlySar as a function of time over 120 min (A), 240 
min (B), and 480 min (C) in PEPT1
+/+
 (wild-type) and PEPT1
-/-
 (KO) mice following a 


















































































































Figure 5.3  Plasma concentrations of GlySar as a function of time over 120 min (A), 240 
min (B), and 480 min (C) in PEPT1
+/+
 (wild-type) and PEPT1
-/-
 (KO) mice following a 


















































































































Figure 5.4  Plasma concentrations of GlySar as a function of time over 120 min (A), 240 
min (B), and 480 min (C) in PEPT1
+/+
 (wild-type) and PEPT1
-/-
 (KO) mice following a 


















































































































Figure 5.5  Plasma concentrations of GlySar as a function of time over 120 min (A), 240 
min (B), and 480 min (C) in PEPT1
+/+
 (wild-type) and PEPT1
-/-
 (KO) mice following a 





















































































Figure 5.6  Dose-corrected cumulative partial area under the plasma concentration-time 
curves vs. dose of GlySar in PEPT1
+/+
 (wild-type) and PEPT1
-/-
 (KO) mice after an oral 
gavage administration.  Data are expressed as mean ± S.E. (n = 4-6). * p < 0.05;  *** p < 
















































































































Figure 5.7  Cumulative partial AUCs (area under the plasma concentration-time curves) 
of GlySar as a function of time over 120 min (A), 240 min (B), and 480 min (C) in 
PEPT1
+/+
 (wild-type) and PEPT1
-/-
 (KO) mice following a 1 nmol/g oral gavage dose.  















































































































Figure 5.8  Cumulative partial AUCs (area under the plasma concentration-time curves) 
of GlySar as a function of time over 120 min (A), 240 min (B), and 480 min (C) in 
PEPT1
+/+
 (wild-type) and PEPT1
-/-
 (KO) mice following a 10 nmol/g oral gavage dose.  















































































































Figure 5.9  Cumulative partial AUCs (area under the plasma concentration-time curves) 
of GlySar as a function of time over 120 min (A), 240 min (B), and 480 min (C) in 
PEPT1
+/+
 (wild-type) and PEPT1
-/-
 (KO) mice following a 100 nmol/g oral gavage dose.  













































































































Figure 5.10  Cumulative partial AUCs (area under the plasma concentration-time curves) 
of GlySar as a function of time over 120 min (A), 240 min (B), and 480 min (C) in 
PEPT1
+/+
 (wild-type) and PEPT1
-/-
 (KO) mice following a 1000 nmol/g oral gavage dose.  













































































































Figure 5.11  Cumulative partial AUCs (area under the plasma concentration-time curves) 
of GlySar as a function of time over 120 min (A), 240 min (B), and 480 min (C) in 
PEPT1
+/+
 (wild-type) and PEPT1
-/-
 (KO) mice following a 5000 nmol/g oral gavage dose.  









































Figure 5.12  Plasma concentration-time profiles of GlySar in PEPT1
+/+
 (wild-type) and 
PEPT1
-/-
 (KO) mice after intravenous bolus administration of dipeptide at a dose of 10 













































































































































































































































































































Figure 5.13  Tissue concentration (A) and tissue-to-plasma concentration ratio (B) of 
GlySar in PEPT1
+/+
 (wild-type) and PEPT1
-/-
 (KO) mice, 60 min after oral gavage 
administration of dipeptide at 10 nmol/g.  Data are expressed as mean ± S.E. (n=6 ).  * p 

























































































































































































































































































Figure 5.14  Tissue concentration (A) and tissue-to-plasma concentration ratio (B) of 
GlySar in PEPT1+/+ (wild-type) and PEPT1-/- (KO) mice, 8 h after oral gavage 
administration of dipeptide at 10 nmol/g.  Data are expressed as mean ± S.E. (n=6 ).  * p 














































































































































































































































































































































Figure 5.15  Tissue concentration (A) and tissue-to-plasma concentration ratio (B) of 
GlySar in PEPT1
+/+
 (wild-type) and PEPT1
-/-
 (KO) mice, 8 h after intravenous bolus 
administration of dipeptide at 10 nmol/g.  Data are expressed as mean ± S.E. (n=6).  * p < 














































Figure 5.16  Metabolic stability of GlySar in PEPT1
+/+
 (wild-type) and PEPT1
-/-
 (KO) 
mice urine over 8 hours (A) and over 24 hours (B)  after oral dose administration of 








Table 5.1  Ration of extent of GlySar systemic exposure in PEPT1 null mice to wild-type 





Dose (nmol/g) 0-120 min 0-240 min 0-480 min 
1 0.41 0.57 0.75 
10 0.40 0.52 0.70 
100 0.44 0.57 0.76 
1000 0.44 0.57 0.70 


















20-120 min 240-480 min 
Wild-type PEPT1 KO Ratio Wild-type PEPT1 KO Ratio 
1 0.64 0.27 0.42 0.66 0.61 0.93 
10 0.68 0.28 0.42 0.73 0.64 0.88 
100 0.67 0.30 0.45 0.67 0.62 0.94 
1000 0.56 0.27 0.48 0.57 0.47 0.82 
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MEASUREMENT OF SKPT INTRACELLULAR VOLUME 
The intracellular volume of SKPT cells was measured by the 3-O-methyl-D-
glucose method (Kletzien et al., 1975; Pollock et al., 1986) in glucose-free media.  The 
cell monolayers were washed and preincubated apically with 0.4 ml of pH 6.0 buffer and 
basolaterally with 1.2 ml of pH 7.4 buffer for 10 min at 37
o
C.  The buffers were then 
removed and fresh buffer (0.4 ml pH 6.0 or 1.2 ml pH 7.4 containing [
3
H]3-O-methyl-D-
glucose (3-OMG) and [
14
C]mannitol; 1 mM, 5 mM, and 10 mM of each) was added to 
the apical and basolateral compartments, respectively, in presence of 200 μM of 
phloridzin (an inhibitor of Na
+
-coupled glucose cotransport).  After 300 minutes of 
incubation (determined from Fig A.1) at 37
o
C, the uptake buffers were aspirated from 
both compartments and the monolayers were washed 5 times from both sides with ice-
cold buffer containing 100 μM of phloretin (an inhibitor of facilitated diffusion).  The 
filters with monolayers were then detached from the chamber, placed in a scintillation 
vial, and the cells were solubilized with 0.2 M NaOH and 1% SDS.  Radioactivity was 
measured in solubilized cells with a dual-channel liquid scintillation counter (Beckman 
LS 6000 SC; Beckman Coulter Inc., Fullerton, CA).  Uptake of 3-O-methyl-D-glucose 
was normalized for amount of protein per well, and the slope of uptake vs. concentration 
was taken as the intracellular volume of SKPT cells.  Thus the intracellular volume of 






Kletzien RF, Pariza MW, Becker JE and Potter VR (1975) A method using 3-O-methyl-
D-glucose and phloretin for the determination of intracellular water space of cells in 
monolayer culture. Anal Biochem 68:537-544. 
Pollock AS, Warnock DG and Strewler GJ (1986) Parathyroid hormone inhibition of 













































Figure A.1 Intracellular accumulation of 5 mM 
3
H-3-OMG ((1.6 µCi/well) and 
14
C-
mannitol (0.5 µCi/well) as a function of time in SKPT cell monolayers at 37°C.  The 
apical compartment buffer pH was 6.0 and basolateral compartment buffer was 7.4.  Data 











































Figure A.2  Intracellular accumulation of 
3
H-3-OMG ((1.6 µCi/well) and 
14
C-mannitol 
(0.5 µCi/well) as a function of concentration (i.e., 1, 5, and 10 mM) in SKPT cell 
monolayers at 37°C for 300 minutes.  The apical compartment buffer pH was 6.0 and 







COMPARISON OF WATER FLUX MEASUREMENTS FOR MOUSE IN SITU 
SINGLE-PASS INTESTINAL PERFUSION 
 
In order to evaluate the use of PEG 4000 as a non-absorbable marker, 3 different 
methods of estimation for water absorption/secretion (PEG 4000, inulin and gravimetric) 
during mouse in situ singles-pass intestinal perfusion were compared in wild-type and 
PEPT1 knockout mice.  Concentration of drug coming out of perfused intestine is 
corrected for water flux by a correction factor according to Eq. 2, 4 and 6.   The 
correction factors for water absorption/secretion were estimated by Eq. 1 for non-
absorbable marker PEG 4000, by Eq. 3 for non-absorbable marker inulin 5000, and by 
Eq. 5 for gravimetric method.  (Refer to chapter 4, method section for experimental 
procedure.) 
Use of non-absorbable marker PEG 4000 





  Eq. 1 












Use of non-absorbable marker inulin 




 Eq. 3 






  Eq. 4 
 
Use of gravimetric method 











   Eq. 6 
where Cperfusate is the actual concentration of drug in the exiting perfusate, and PEGin and 
PEGout are the inlet and outlet concentrations of PEG 4000 and Inulinin and Inulinout are 
the inlet and outlet concentrations of Inulin 5000.  Vin-total and Vout-total are the total volume 
of solution entered and exited the perfused intestinal segments.  Cout represents the 
corrected outlet concentrations of drug. 
If correction factor > 1, then there is some loss of water due to water absorption 
from the lumen to intestine, thus Cout is more concentrated and thus should be corrected 




If correction factor < 1, then there is some gain of water due water secretion from 
the intestine into the lumen, thus Cout is more diluted and should be corrected to a higher 
concentration by dividing by the correction factor of < 1 
Based on the results from the comparison study of different water flux 
measurements, PEG 4000 (compared to gravimetric method and inulin) appears to 
overestimate the water secretion by approximately 21% for mouse intestinal perfusion in 
both wild-type and PEPT1 knockout mice (Fig. B.1).  Therefore, all of the water flux 
corrections assessed by PEG 4000 (in Chapter 4) were adjusted by an average water flux 
correction of 14%, as determined by the 3 methods (i.e., non-absorbable markers PEG 




















































Figure B.1 Correction factors for water absorption/secretion during the mouse in situ 
intestinal perfusion estimated by non-absorbable markers (i.e., PEG 4000, inulin 5000) 
and gravimetric methods in wild-type and PEPT1 knockout mice.  Data are expressed as 
mean ± SE (n=4-8). 
 
